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 Acute Lymphoblastic Leukemia (ALL) is the most commonly diagnosed 
malignancy in children (Pui, 2000; Steen & Mirro, 2000; American Cancer Society, 
2009; Westlake & Bertolone, 2002). Modern advances in cancer treatment, such as 
combination chemotherapy (Ettinger, Bond, & Sievers, 2002; Rodman & Reed, 2009), 
have increased survivorship of ALL to nearly 85% (Westlake & Bertolone, 2002). This 
new population of ALL survivors is displaying a unique profile of cognitive late effects 
that are a result of the treatment (e.g. chemotherapy) which while effective in eradicating 
the disease, has neurotoxic properties (American Cancer Society, 2009). Late effects have 




spatial skills, and processing speed, but the most commonly seen late effects are in the 
areas of attention and memory (e.g. Askins & Moore, 2008; Cullen, Derrickson, & Potter, 
2002; Leigh, 2000). While working memory is a skill that depends on both attention and 
memory (Baddeley 2000) and is important in both academic performance and life skills 
(Dark & Benbow, 1991; Geary, Hoard, & Hamson, 1999), it is relatively unstudied in this 
population. 
 The purpose of this study was to investigate working memory abilities in 
survivors of pediatric ALL. Working memory skills in this population were compared to 
both sample and population IQ. Comparisons of verbal and nonverbal working memory 
and male and female working memory skills were compared as well. First, working 
memory, as measured by a composite, was not found to be significantly impaired when 
compared to sample and population mean IQ. However, a single subtest, Digit Span 
Backward from the Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV; 
Wechsler, 2003), when compared to IQ outside the composite, was found to be 
significantly below IQ for both the sample and population mean. Second, no gender 
differences were found for working memory abilities. Finally, there was no difference 
between nonverbal and verbal working memory performance. While the results were 
nonsignificant, verbal working memory was worse than nonverbal working memory, 
which was the opposite of the hypothesized pattern. Implications, recommendations, and 
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Chapter I: Introduction 
 Cancer is the leading cause of death in children under the age of 15 (National 
Childhood Cancer Foundation, 2009). Among the cancers diagnosed each year, Acute 
Lymphoblastic Leukemia (ALL) is the most commonly diagnosed, affecting roughly one 
per thousand children (American Cancer Society, 2009). Due to medical advances over 
the past 40 years, survival rates of ALL have increased from 15% to 85%, with over 90% 
of children diagnosed with ALL surviving five years post diagnosis (National Childhood 
Cancer Foundation, 2009). Treatment protocols including chemotherapy, tumor resection, 
radiation, and combinations of those methods have been researched, modified, and 
improved, resulting in dramatically higher rates of survival. 
  While the dramatically increased survival rates are benevolent, the methods used 
to treat these children may produce damaging side effects. Most current treatment 
protocols act directly on the Central Nervous System (CNS); chemotherapy to the CNS 
with methotrexates is currently the most common treatment protocol for newly diagnosed 
cases of ALL (Margolin, Steuber & Poplack, 2002; Moe, 2003). While methotrexates 
improve survival rates (Moe, 2003), it is highly neurotoxic. Thus, the treatment protocol 
for ALL, while highly effective in increasing survival rates, may be associated with 
cognitive decline for individuals who survive the disease. 
 Since the increased survival rate of those diagnosed with ALL is a product of 
more recent treatment protocols, literature investigating the abilities and well being of 




cognitive abilities in survivors of ALL has generated common particular cognitive 
vulnerabilities to treatment on the CNS. Children who have undergone neurotoxic 
treatments such as chemotherapy may be susceptible to developing long-term 
neurocognitive deficits which are commonly called late effects. The most common late 
effects seen in survivors of ALL negatively impact short term memory and attention 
processes (Jansen et al., 2008; Kingma, Dommelen, Mooyaart, Wilmink, Deelman & 
Kamps, 2001; Mountour-Proulx et al., 2004; Thompson et al., 2001). Other reported  
problems associated with late effects include math performance (Kaemingk, Carey, 
Moore, Herzer, & Hutter, 2004), nonverbal skills (Brown et al., 1998; Carey et al., 2006), 
and fine motor functioning (Jansen et al., 2008). Additionally, a diagnosis prior to age 5 
correlates with more severe late effects (Copeland et al., 2001), and ALL is most often 
diagnosed before age 5. 
 Attention and short-term memory are extremely important cognitive processes 
that may affect other systems of cognitive functioning in individuals. Working memory, 
the ability to hold information in immediate attention, apply mental control, and 
manipulate the information (Floyd, 2003), involves both attention and memory. Working 
memory is involved in the cognitive processes used to execute both attention and 
auditory processing (Dark & Benbow, 1991; Geary, Hoard, & Hamson, 1999; Hale, 
Fiorello, Bertin, & Sherman, 2003; Knudsen, 2007; Sander & Poeppel, 2006). The most 
common theory of working memory has been developed by Baddeley and Hitch (1974), 
who outlined three components of working memory: the phonological loop (interprets 




information), and the central executive (supervises and controls input and output of 
information). This theory of working memory, as well as the existence of its components, 
is well-supported by research (Baddeley & Hitch, 1994; Baddeley, Lewis, & Vallar, 
1984; Bishop & Robson, 1989). In order for the working memory system to successfully 
manipulate information an individual must (1) attend to the information and (2) hold the 
information in short-term memory. Working memory is implied in the successful 
completion of many school and real life activities, such as note-taking, processing 
auditory directions, and performing mental calculations. 
 Given the components necessary to execute working memory processes and 
common late effects of children treated for ALL, it may be implied that working memory 
processes would be negatively affected by neurotoxic treatments such as chemotherapy 
and radiation. However, given the relatively brief history of the knowledge of late effects 
in children treated for ALL, this is an area that little research has been dedicated to.  
 The purpose of this study is to determine whether working memory is affected by 
neurotoxic CNS treatment protocols used on survivors of Acute Lymphoblastic 
Leukemia. Research has shown that treatment protocols for ALL have resulted in the 
decline of short-term memory and attention processes. Research has also shown that 
short-term memory and attention are integral to the working memory process. However, 
there is little research on whether working memory deficits are evident in survivors of 




Chapter II: Review of the Literature 
 A review of the literature in the areas of pediatric cancer and acute lymphoblastic 
leukemia (ALL), the treatment of ALL, late effects of treatment for ALL, and the 
cognitive skill of working memory will be presented. By critically analyzing the current 
research base in these areas, a foundation for conducting the present study will be 
established. The first section discusses pediatric cancer and its incidence, then acute 
lymphoblastic leukemia specifically, including its incidence and survival rates. Next, a 
detailed discussion of possible treatments for ALL, including chemotherapy, radiation, 
and transplants will be presented. Current treatment protocols for ALL will be presented 
here as well. The next section includes a description of late effects of cancer and a 
discussion of common late effects seen in survivors of ALL, including attention and 
memory deficits. Demographic and developmental considerations related to late effects 
will also be discussed in this section. The last section discusses the cognitive ability of 
working memory and its relation to various academic deficits. 
Cancer 
 Cancer is a disease that begins when cells in an individual‟s body begin to grow 
out of control (American Cancer Society, 2009). In the United States, cancer is the 
second leading cause of death, and nearly half of all men and one third of all women will 
develop cancer during their lifetimes (American Cancer Society, 2009). Cancer affects 




 There are many different varieties of cancer, but each type begins due to 
uncontrolled growth of abnormal cells caused by a genetic mutation. In children, normal 
cells grow and divide at a rapid rate to allow for growth; as adults, cells grow and divide 
at a slower rate. Cancerous cells are different from both child and adult normal cells 
because not only do they grow and multiply at a quicker rate, but they also outlive normal 
cells (American Cancer Society, 2009). They can also invade healthy cells and turn them 
into cancerous cells (American Cancer Society, 2009). When cancer affects an individual, 
it may begin as a single cell and proceed to invade healthy cells, then multiply (Steen & 
Mirro, 200).While all cancers share this rapid growth and invasion pattern, the rates of 
growth differ between types and often require very different courses of treatment 
(American Cancer Society, 2009). 
Incidence of Pediatric Cancer. 
 Among diseases that affect children and adolescents, cancer is the most common. 
Approximately 12,500 children and adolescents (or 1-2 children per 10,000) will develop 
some form of malignant cancer each year (National Childhood Cancer Foundation; Daly, 
Kral & Brown, 2008).  It is also estimated that one in 350 American children will develop 
cancer before the age of 20 (Steen & Mirro, 2000). Cancer is the second leading cause of 
death in children ages 1 to 14 years, following accidents (Foley & Fergusson, 2002).  
Additionally, the incidence of cancer in children has been increasing slightly, but 




 There are many different types of cancer that affect the pediatric population, and 
certain types of cancer more commonly affect children than adults. In adults, cancer most 
commonly affects epithelial tissues, which is extremely rare in the pediatric population. 
In children, cancers most often arise from deep-seated tissue (e.g. bone marrow, central 
nervous system) which is less common in adulthood (Ruccione, 2002).  Steen & Mirro 
(2000) report that leukemia, lymphoma, and Central Nervous System (CNS) cancers are 
the predominant types found in children and adolescents. Other common types of cancer 
found in children are CNS tumors (19% of diagnoses), Lymphomas (12%), 
Neuroblastomas (8%), Soft Tissue Sarcomas (6%), Genito-urinary Tumors (6%), 
Ostesarcomas (5%) and Retinoblastomas (2%; Steen & Mirro, 2000). 
Leukemia.  
 Leukemia is a type of cancer that typically starts in the bone marrow and can 
spread to the blood, where it can travel to and infect various organs (American Cancer 
Society, 2009). Leukemia is different from many cancers in that it does not form tumors; 
instead, it circulates throughout the blood forming organs and eventually through the 
blood.  
 Various sources name leukemia as the most common type of cancer in the 
pediatric population (American Cancer Society, 2009; Pui, 2000; Steen & Mirro, 2000). 
Leukemias reportedly affect between 25 and 31 percent of children diagnosed with 
cancer (Steen & Mirro, 2000; Westlake & Bertolone, 2002). According to the American 




is more commonly found in children than adults as there is a peak in diagnosis between 
ages 2 and 5 years (Pui, 2000).  
 Onset of leukemia is usually sudden. A child with leukemia will usually seek 
medical attention with the complaint of fever, sometimes accompanied by fatigue (Pui, 
2000). Some children will also present with bone or joint pain, headache, vomiting, 
weight loss, and other symptoms. It should be noted that these symptoms may 
accompany a variety of different pediatric illnesses (flu, cold, infection) and these 
illnesses must be ruled out before leukemia can be diagnosed. When the individual‟s 
symptoms are not accounted for by another childhood illness, the patient is referred to a 
hemotology/oncology specialist. Once an individual is seen by a hematologist/oncologist, 
the diagnosis of leukemia can be confirmed. The exam usually includes workups in 
various systems, including blood, urine, and bone marrow analysis. The diagnosis of 
leukemia can be confirmed by the presence of leukemic cells in the bone marrow. Bone 
marrow in a patient with leukemia typically filled with leukemic lymphoblasts 
(lymphoblast cells affected and changed by leukemia; Pui, 2000). Once a diagnosis of 
leukemia has been confirmed, the patient often immediately begins induction 
chemotherapy (discussed later), and the initial symptoms (e.g. fever, bone pain) will 
subside in one to three days (Pui, 2000). 
 There are several types of leukemia: Acute Lymphoblastic Leukemia (ALL), 
Acute Myelogenous Leukemia (AML), and Hybrid Leukemia. ALL, the most common of 




that form white blood cells, red blood cells, or platelets. Hybrid leukemias have features 
of both ALL and AML, and these cases are extremely rare (American Cancer Society, 
2009).  
 Acute Lymphoblastic Leukemia (ALL).  
Among leukemias, the most common type is Acute Lymphoblastic Leukemia 
(ALL; American Cancer Society, 2009; Pui, 2000; Steen & Mirro, 2000; Westlake & 
Bertolone, 2002). ALL is commonly referred to as the most common malignancy 
diagnosed in the pediatric population. ALL reportedly accounts for 70 percent of cases of 
leukemia in individuals ages 19 and younger, and 25% of all pediatric cancers (Westlake 
& Bertolone, 2002). As with other leukemias, the typical age of onset is between 2 and 5 
years. The frequency of ALL varies in different geographic and ethnic groups. Caucasian 
children are most likely to be affected by ALL and black children are least likely to be 
affected world-wide (Pui, 2000). Countries vary in the percentage of children affected by 
ALL, and the general consensus is that more industrialized countries have a higher 
incidence of ALL due to both environmental (underdiagnosis in developing countries, 
varied exposure to infections, death from other causes) and genetic factors (e.g. Down 
Syndrome; Westlake & Bertolone, 2002). Additionally, males are more likely than 
females to have a diagnosis of ALL (Pui, 2000). 
Survival Rates of ALL. 
 Due to vast improvements in treatment protocols, the survival rates of ALL have 




with ALL, he or she was likely to die, usually within a period of months. In 1963, the 
survival rate of childhood cancer (5 years post diagnosis) was 28%; thirty years later, the 
survival rate was 72% (Steen & Mirro, 2000). Currently, over 80% of children diagnosed 
with ALL will survive at least 5 years post diagnosis (Westlake & Bertolone, 2002). 
Recent survival rates are reported to be between 72 and 95% for children diagnosed with 
ALL. As medical technologies continue to advance and the knowledge of the efficacy of 
various treatments increases, it is expected that survival rates will continue to climb. In 
1999, less than 3 in 100,000 people ages 15 and younger died from cancer (Steen & 
Mirro, 2000).  
Treatment of ALL 
 Over the last few decades, the treatment of ALL has gone through various 
iterations, leading to the present, in which 80% of children diagnosed with ALL survive 
at least 5 years post diagnosis. This dramatic increase is due to the increase in medical 
knowledge of the disease, its course, individual factors, and improvement in medical 
technologies. Currently, an individual diagnosed with ALL may receive treatment in the 
form of chemotherapy, radiation, bone marrow or stem cell transplants, or any 
combination of these treatments. 
Chemotherapy. 
 Chemotherapy refers to the use of drugs to kill cancer cells (American Cancer 
Society, 2009; Rodman & Reed, 2009). The drugs used in chemotherapy may enter the 




fluid, or consumed in capsule form. When treating ALL with chemotherapy, either alone 
or in conjunction with other treatments, it is common to use a combination of drugs 
instead of a single drug (Rodman & Reed, 2009). This is called combination 
chemotherapy, and certain combinations are implicated when treating specific cancers 
(Ettinger et al., 2002). Using drugs in combination has several advantages. First, the 
combination of drugs is preferred because individual cancer cells in ALL may have more 
than one abnormality or there may be several different types of cancer cells in an 
individual with ALL. Specific drugs are indicated to target certain abnormalities, which is 
why multiple drugs are often used to ensure that each of the abnormalities is eradicated. 
Second, the use of multiple drugs in an individual can be beneficial in that cancer cells 
have the capability to become resistant to drugs. Cancer cells may mutate or evolve over 
time, thus making them immune to particular drugs. By using a combination of drugs in 
chemotherapy, it reduces the likelihood that the drugs will become ineffective due to 
evolution of cancer cells in an individual (Rodman & Reed, 2009). Third, clinical studies 
have shown that certain drugs in combination show an enhanced effect when working 
together as compared to separate administrations (Ettinger et al., 2002). Thus, using 
specified chemotherapy drugs in combination increases efficacy of treatment. Common 
drugs used in chemotherapy include vincristine, methotrexates, prednisone, 
mercaptopurnine, and hydrocortisone (Cheok & Evans, 2009). 
 Chemotherapy is a very popular treatment in individuals diagnosed with ALL as 
80% of patients with ALL can survive with chemotherapy alone (Pui, 2000). There are 




treatment: Induction, Consolidation, and Maintenance (American Cancer Society, 2009). 
The entire course of chemotherapy treatment usually lasts between two and three years. 
 Induction is the first phase of chemotherapy. Its purpose is to quickly enter the 
system and destroy as many cancer cells in the least possible amount of time (American 
Cancer Society, 2009). In children with ALL, this is accomplished by injecting 
chemotherapy directly into the cerebro-spinal fluid (CSF) to prevent the cancer from 
spreading to the central nervous system (CNS). This method of delivery is called 
intrathecal chemotherapy and the drugs are often injected directly to the spine via lumbar 
puncture (American Cancer Society, 2009). The induction phase is complete once more 
that 99.9% of cancer cells have been destroyed. Once the induction phase is complete, the 
patient is considered to be in remission, and more that 95% of children diagnosed with 
ALL will enter remission after 1 month of induction chemotherapy (American Cancer 
Society, 2009). 
 The consolidation phase follows remission after the induction phase. The purpose 
of consolidation is to destroy the remaining cancer cells. The consolidation phase uses 
combination chemotherapy as well, and common drugs administered include 
cyclophosphamide, cytarabine, methotredate, and asparaginase (Westlake & Bertolone, 
2002). These drugs are often administered intrathecally. The intensity of chemotherapy in 
the consolidation phase may vary depending on patient risk (e.g. amount of leukemic 




 The final phase of chemotherapy is maintenance, and its purpose is to destroy the 
remaining cancer cells (American Cancer Society, 2009). It is designed to provide a 
prolonged period of therapy to destroy all remaining cancer cells, and is associated with 
daily therapy. The maintenance phase often includes daily oral doses of chemotherapy 
(e.g. mercatopurine) in combination with methotrexate (Westlake & Bertolone, 2002). 
Other drugs may be administered as well during maintenance if the patient has a higher 
risk or an increased chance of relapse. 
 It is important to note that while chemotherapy is a very effective treatment for 
ALL, it is associated with dangerous and uncomfortable side effects. Common immediate 
side effects of chemotherapy include hair loss, mouth sores, loss of appetite, diarrhea, 
nausea, lowered resistance to infection, bruising, easily bleeding, and fatigue (American 
Cancer Society, 2009). The drugs used in chemotherapy are toxic to cancer cells, which 
makes them effective at eradicating the disease, but the drugs are also toxic to normal 
cells, subsequently harming the patient while curing him or her (Rodman & Reed, 2000). 
In modern medical research, certain drugs have been discovered that are very effective at 
killing cancer cells, but are also highly toxic to healthy cells. A good example of this is 
methotrexates. Methotrexates are a type of chemotherapy agent used to treat many 
cancers, including ALL, in the pediatric population. It destroys cancer cells by interfering 
with folic acid (Rodman & Reed, 2000). This quality has been associated with very 
effective treatment of ALL, as methotrexates have proved to be highly toxic to leukemic 
cells (Cheok & Evans, 2009). However, methotrextates have also proved to be highly 




(Rodman & Reed, 2000). Immediate complications include nausea, vomiting, low blood 
counts, mouth sores, and skin rashes. These side effects are common in many 
chemotherapy agents. However, long term side effects have been discovered as well, 
including seizures, intellectual impairment, kidney damage, and liver damage. Since the 
side effects are so serious, the use of methotrexates is monitored carefully; however, it is 
so effective that it is commonly used in chemotherapy. 
Thus, balance is crucial in the administration of chemotherapy; treatment 
protocols are balanced to use the least amount of chemotherapy possible in order to treat 
an individual‟s ALL in order to reduce toxicity to normal cells (Cheok & Evans, 2009).  
Radiation. 
 Radiation therapy is the use of high-energy radiation to kill cancer cells 
(American Cancer Society, 2009). Children diagnosed with ALL who receive radiation 
therapy typically have cancer that has spread to the membranes which cover the brain or 
testicles. It may also be used in children who were originally treated with ALL but who 
experienced a relapse of the disease affecting the CNS or testicles (Cullen et al., 2002). 
 In the past, radiation therapy was one of the most preferred methods of treatment 
for children diagnosed with ALL.  Like other treatments which kill both cancerous and 
non-cancerous tissue, non-cancerous tissue destroyed by radiation recovers much better 
than cancerous tissue (Merchant, 2000). This makes radiation an effective treatment for 
many cancers, ALL included. Radiation to the brain also proved to decrease the risk of 




However, current research has shown that radiation may cause problems in 
learning and growth (American Cancer Society, 2009; Merchant, 2000). Even at very low 
doses, radiation has been shown to be responsible for long-lasting cognitive and physical 
side effects (American Cancer Society, 2009). Additionally, an increase in dosage is 
correlated with more significant impairments (Weiner & Simone, 2003). Thus, treatment 
teams working with children diagnosed with ALL typically tend to discourage the use of 
radiation unless other treatments with less severe side effects (e.g. chemotherapy) are not 
effective in treating the disease (Merchant, 2000). 
 Transplants. 
 A small percentage of children diagnosed with ALL require more extreme 
treatment than chemotherapy or radiation can provide. Children whose chances of 
survival are slim with chemotherapy, radiation therapy, or a combination of the two, are 
eligible for bone marrow or stem cell transplants. Children whose ALL recurs within 6 
months or less following remission are also often treated with transplants (American 
Cancer Society, 2009; Horwitz, 2000). The goal of both bone marrow and stem cell 
transplants is to use extreme chemotherapy to destroy all of the cancer and then provide 
the child with healthy blood-forming cells to recover from the damage caused by the 
cancer-killing drugs. 
 Prior to the transplant, children are given extremely high doses of chemotherapy 
which destroys all of the cancerous cells. However, the doses are so high that the 




individuals necessitate a bone marrow or stem cell transplant (American Cancer Society, 
2009). Bone marrow transplants use healthy bone marrow cells from a donor (allogeneic 
transplant), from the patient (autologous transplant) or from an identical twin (syngenic 
transplant; Horwitz, 2000). Stem cell transplants use blood-forming stem cells with the 
hope that within 3 to 4 weeks the stem cells will begin to produce healthy blood cells in 
the child‟s bone marrow (American Cancer Society, 2009). As with bone marrow 
transplants, stem cell transplants may be allogeneic or autologous, however, the 
autologous stem cell transplants are less commonly used because a child‟s own stem cells 
may contain cancer (American Cancer Society, 2009).  
Current Treatment Protocols. 
 Over the last several decades, the treatment of ALL has taken great strides. The 
general rule that treatment teams abide by when making decisions about an individual‟s 
treatment is to provide the least aggressive approach possible to reduce neurotoxicity 
(Pui, 2000). In over 80% of cases, chemotherapy alone is successful in eradicating the 
disease (Pui, 2000). 
 When a child is referred to an oncologist and a diagnosis of ALL is confirmed, the 
typical first step in treatment is to clear the child of any current infection (e.g., fever) 
before beginning chemotherapy. Once this is complete, the induction phase of 
chemotherapy can begin in which the child typically is given a corticoid (e.g. prednisone) 
with vincristine and L-asparaginase, sometimes accompanied with anthracycline. With 




The induction phase usually lasts around 6 weeks for patients with ALL (Cheok & Evans, 
2009). Then, the consolidation phase of chemotherapy is administered, which continues 
to reduce cancerous cells. The typical drugs used in this phase are methotrexates and 
mercpatopurene, and this phase typically lasts roughly 2 weeks (Cheok & Evans, 2009; 
Pui, 2000). Then, the continuation treatment, or maintenance phase is administered. The 
continuation phase typically involves daily administration of mercaptopurine combined 
with weekly administration of methotrexates (Cheok & Evans, 2009; Pui, 2000).While 
many pediatric cancers utilize induction, consolidation, and continuation phases of 
chemotherapy to eradicate the disease, ALL requires a much longer continuation phase 
than other types of pediatric cancers.  
 ALL has been treated with chemotherapy only in the last 50 to 60 years (Rodman 
& Reed, 2000), and it has become the preferred method of treatment for these patients. 
The use of current treatment protocols involving combination chemotherapy, as described 
above has been continually improved to arrive at the current survival rates of 80%. 
Typically, doctors will use combination chemotherapy alone to treat ALL in an 
individual if possible, using other methods of treatment (radiation, transplants) only when 
necessary (Cheok & Evans, 2009). Some of the most recent ALL treatments are being 
informed by genetic markers which indicate certain factors, influencing which agents to 
use. For instance, certain genetic markers in an individual may indicate increased 
resistance to a certain drug or exaggerated toxicity with another drug. Thus, the genetic 




individuals (Cheok & Evans, 2009). In the future, particular treatment protocols may be 
designed and implemented based on genetic screening upon diagnosis. 
Late Effects of Treatment for ALL 
 While the treatment for ALL (e.g., chemotherapy, radiation) is effective at killing 
cancerous cells, it is also effective at damaging normal tissue. Late effects of treatment 
are negative effects caused by the injury that the cancer treatment causes to the healthy 
cells in the body (American Cancer Society, 2009). Factors that contribute to late effects 
include lack of cell nourishment, chronic cell injury, death of healthy cells, and scar 
tissue. Chemotherapy damages healthy cells by killing healthy cells along with cancerous 
cells. Radiation damages healthy cells by using high energy rays to kill cancer cells, 
which damages normal cells as well. While general consensus states that late effects are 
more severe in patients treated with radiation and chemotherapy when compared to 
patients treated with chemotherapy only, recent literature indicates that 
neuropsychological deficits do occur in patients treated only with chemotherapy (Hobbie, 
Ruccione, Harvey, & Moore, 2002). 
 While there are immediate effects of treatment (e.g. nausea, fatigue, pain, etc.), 
late effects typically do not show up immediately following completion of treatment 
(Weiner & Simone, 2003). These effects are called late effects because they typically 





 Late effects can be seen in physical, cognitive, and psychological realms. Physical 
late effects include injury to eyesight, hearing, growth, thyroid, sexual development, 
cardiovascular system, respiratory system, muscles, bones, and teeth (American Cancer 
Society, 2009). Neuroanatomic late effects can be present as well after treatment for 
ALL, and may include diffuse brain atrophy, perfusion defects, and decreased white 
matter (Hobbie et al., 2002). In children treated for ALL, it is hypothesized that 
methotrexates (used in chemotherapy) are responsible for perfusion defects (Hobbie et 
al., 2002). Perfusion refers to blood flow in the brain; too little perfusion pressure 
restricts blood to the brain and too much perfusion pressure can increase intercranial 
pressure. The most common cognitive late effects following treatment for ALL are 
deficits in attention and memory; other cognitive late effects can include a decline in 
academic achievement, fine motor functioning, processing speed, and visual-perceptual 
skills. Children treated for leukemia, including ALL, are susceptible to cognitive late 
effects of treatment (Weiner & Simone, 2003). When including all children created for 
cancer, roughly 50 to 60% will have risk of neurocognitive impairment following 
treatment (Weiner & Simone, 2003).These neurocognitive late effects, along with other 
cognitive late effects, will be discussed in detail. Emotional late effects such as anxiety or 
depression may be present as well. Late effects are most commonly seen in individuals 
who receive treatment directly to the central nervous system (e.g. intrathecal 
chemotherapy, radiation to brain; American Cancer Society, 2009). Pediatric patients 
with ALL are more susceptible to late effects of treatment because children and 





 ALL can affect children and adolescents of both genders, any age, and any 
ethnicity. However, rate of diagnosis, susceptibility to late effects, survival rates, and 
reaction to treatment can vary greatly across demographic differences.  
Age at Diagnosis.  
While there are some discrepancies between studies, it is generally reported that 
ALL is most frequently diagnosed between ages 2 and 5 years (Pui, 2000; Raccione, 
2002; Westlake & Bertolone, 2002). While ALL can affect individuals of all ages, it 
typically affects young children the most. Survival rates of ALL are the highest in 
children in the youngest age group (ages 1-4 at diagnosis; survival = 85%), and survival 
rate steadily declines as the age at diagnosis increases (Westlake & Bertolone, 2002). It is 
hypothesized that the different age groups (1-4 years, 5-9 years, 10-14 years, and 15-19 
years) may be typified by different biologic subtypes that are associated with different 
survival rates (Westlake & Bertolone, 2002). 
 While young children with ALL have the highest survival rates, they also have the 
highest levels of susceptibility for developing late effects. Late effects are most common 
in children who are 5 years or younger at the time of treatment (American Cancer 
Society, 2009). Cognitive late effects are particularly salient for the younger age group 
(Brown et al., 1998; Hobbie, 2002; Von der Weid et al., 2002; Weiner & Simone, 2003). 
While late effects can also be present in survivors of ALL in the older age at diagnosis 




(Eiser, 1998). Even very low doses of treatment have been shown to cause late effects in 
very young children (Waber, 200).   
 A study by Leung, Hudson, Zhu, Rivera, Riveiro, Sandlund et al (2000) 
investigated academic late effects in survivors of ALL who received radiation treatment 
at ages 2 years and younger. They discovered that for this particular set of patients, there 
was an 18% increase in academic difficulties for each month younger in age when 
radiation was received. For example, a child who received radiation at 15 months will 
have an 18% decrease in academic functioning when compared to a child who received 
radiation at 16 months. 
  It is hypothesized that younger children are more vulnerable to late effects due to 
rapid growth and development that occurs at younger ages (Leung et al., 2000). Young 
children are often treated during critical developmental periods, which may be interrupted 
(Weiner & Simone, 2003) by the acquired insult of cancer treatment. When a young child 
is diagnosed with ALL, both the disease and the treatment potentially interrupt typical 
growth and development.  
Gender.  
Cancer incidence is generally higher for males than females, and this is true for 
ALL as well (Raccione, 2002; Westlake & Bertolone, 2002). In children diagnosed with 
ALL, there are slightly higher survival rates for females than males (Westlake & 
Bertolone, 2002). However, female survivors of ALL are more susceptible to developing 




Gamis & Nesbit, 1991; Leung et al., 2001; Palmer et al., 2001; Ris, Packer, Goldwien, 
Jone-Wallace, & Boyett, 2001; Spencer, 2006). A meta-analysis by Peterson et al. (2008) 
confirmed the increased severity of late effects in female survivors when compared to 
male survivors. The greater risk of late effects for females appears to be present among 
survivors who received radiation and chemotherapy, and survivors who received 
chemotherapy alone (Von der Wied et al., 2002). Hobbie, Ruccinone, Harvey & Moore 
(2002) report that females have a greater risk of developing general cognitive deficits, but 
do not show difficulties in language based academic skills (e.g. reading). Brown et al. 
(1998) report that females displayed significant difficulties on test of nonverbal skills 
when compared to age-matched norms, whereas males did not show significant 
difficulties. 
Ethnicity.  
While ALL affects children in all countries, differences have been found among 
ethnic origins. Raccione (2002) reported that children of African descent have lower 
incidence of diagnosis of ALL than children of Caucasian descent. Westlake & Bertolone 
(2002) concur, stating that ALL is most common in Caucasian children. 
Cognitive Late Effects. 
 Over the past several decades, while treatment for ALL has improved survival 
rates dramatically, cognitive late effects have been discovered. Many researchers have 
documented long-term cognitive effects on attention, memory, nonverbal functioning, 




Askins & Moore, 2008; Cullen et al., 2002; Leigh, 2000). While these late effects appear 
to be more severe following radiation treatment, many cognitive late effects have also 
been found to be present following chemotherapy alone, particularly when methotrexate 
is part of the treatment regimen. 
 IQ.  
While most researchers agree that chemotherapy alone is less damaging to cognitive 
abilities than radiation plus chemotherapy, some evidence for overall cognitive decline 
following chemotherapy regimens does exist. Meta-analysis indicates that, when 
compared to healthy controls, survivors of ALL treated only with chemotherapy 
demonstrate significantly lower IQs, as measured by the Wechsler tests (Peterson et al., 
2008). 
Attention.  
Attention is the ability to focus concentration on one portion of the environment 
at the exclusion of others. Attention is an important ability which impacts both daily and 
academic functioning. Among survivors of ALL, a deficit in attention following 
completion of treatment is one of the most common late effects. 
 Survivors who underwent protocols including radiation therapy as well as 
protocols including only chemotherapy show deficits in overall cognitive ability and 
attention (Cullen et al., 2002). While it has been concluded that late effects are more 




chemotherapy alone, it has been shown that attention is still negatively affected in the 
chemotherapy only group (Ashford et al., 2010; Kingma et al., 2002; Moleski, 2000; 
Reddick et al., 2006; Spencer, 2006; Waber, 2002). These attention deficits have been 
shown to significantly impair academic and home functioning. Weiner & Simone (2003) 
found that many nonverbal functions, especially attention, are impacted by the treatment 
of ALL.   
 Specific deficits in attention are rarely found shortly following completion of 
treatment. It is common to see deficits in attention beginning 3 to 5 years after treatment 
for ALL has been finished (Hobbie et al., 2002). Jain, Brouwers, Okcu, Cirino, and Krull 
(2009) found differential attentional deficits in males and females with significantly 
worse performance in both sexes to be correlated with intensity of treatment. Specifically, 
they found that females performed worse on measures related to the anterior attention 
system (shifting attention) and subcortical attention (sustaining attention) whereas males 
performed worse on measures related to anterior control (inhibition and working 
memory). 
 Memory.  
Memory is a broad ability describing an individual‟s ability to retain knowledge 
and information. There are many different types of memory (e.g. short-term, long-term, 
episodic, semantic, explicit, implicit), and memory is a complex neurological entity. 




and the thalamus (Carlson, 2007). Memory also involves several complex processes, 
including consolidation and retrieval, in order to work properly. 
 As with attention, memory is negatively affected by treatment for ALL (Askins & 
Moore, 2008). Individuals who undergo radiation as well as individuals who undergo 
chemotherapy alone have significant declines in memory functioning post-treatment 
(Waber, 2002). Research has shown that both verbal memory (Waber, 2002) and spatial 
memory (Spencer, 2006; Weiner & Simone, 2003) are diminished in survivors of ALL. 
Memory deficits are considered late effects in survivors of ALL because they typically 
surface 3 to 5 years following the completion of CNS treatment (Hobbie et al., 2002). 
Processing Speed.  
Reduction of white matter in the brain (which will be discussed below) leads to 
less efficient processing of information. White matter volume is typically reduced by 
treatment for ALL, leading to late effects in the area of processing speed, as the brain is 
less efficient following treatment. Processing speed deficits have been found in children 
treated with only chemotherapy (e.g. Ciesielski et al., 1999; Heukrodt, Powazek, Warren, 
& Kennely, 1988). Additionally, a study by Mennes et al. (2005) indicated that 
processing speed abilities in survivors of ALL were significantly impaired and decreased 






Nonverbal Functioning.  
Nonverbal skills include short-term visual memory, processing speed, visual-
motor integration, sequencing ability, attention, and concentration (Weiner & Simone, 
2003). Nonverbal skills typically measured by cognitive testing include copying or 
making designs and solving visual puzzles. 
 As with other typical late effects, nonverbal late effects generally appear 3-5 years 
following completion of CNS treatment in survivors of ALL. Among common late 
effects, it appears that nonverbal late effects are more common across ALL survivors 
than verbal late effects (Weiner & Simone, 2003). Nonverbal late effects are present in 
survivors who received only chemotherapy (no radiation; Brown et al., 1992). A study 
conducted by Brown et al. (1998) suggests that there is an interaction between gender and 
nonverbal late effects, with females performing significantly worse than males on 
measures of nonverbal performance. This is consistent with overall findings that females 
may be more susceptible to cognitive late effects than males. 
 Fine Motor Functioning.  
Fine motor functioning, usually measured by motor speed, gnosis, and strength is 
found to be impaired in survivors of ALL and, like processing speed, may be 
contributable to reduction of white matter in the brain (Aukema et al., 2009). Fine motor 
skills are important in academic skills such as writing and typing. They are also important 





 Fine motor skill defects typically begin to show 3-5 years following completion of 
treatment. Deficits are present in survivors who received only chemotherapy (no 
radiation; Jansen et al., 2008; Kaleita, Reaman, & MacLean, 1999; Moleski, 2000;). 
 Academic Achievement.  
Survivors of ALL typically display below average academic performance when 
compared to their peers. Late effects appear to be present across academic subjects. 
Survivors of ALL were found to have significantly lower academic performance as soon 
as 4 years post-diagnosis (Brown, Sayer, Antoniou, Toogood, & Rice, 1999). Brown et 
al. (1999) found deficits in math, reading, and spelling and Peterson et al. (2008) reported 
math and reading problems in survivors of ALL. However, many researchers are 
discovering that mathematics is more affected than other areas of academic achievement 
in survivors of ALL. Mathematics learning disabilities were found in survivors of ALL 
who were treated with chemotherapy only, as reported by Brown, Madan-Swain, Pais, 
Lambert, Sexson & Ragab (1992). Additionally, a comprehensive review of literature by 
Moleski (2000) confirmed that while academics in general are impacted by treatment for 
ALL, mathematics continually appears as a specific deficit.   
 Academic deficits may be caused by a number of reasons. Since late effects are 
present in a number of higher order skills (e.g. attention, memory, executive function), it 
may be hypothesized that the late effects in other cognitive skills has a negative impact 
on academic skills. For example, if a child has difficulty with short term memory and 




calculations require the child to attend to and remember the problem, in addition to 
carrying out the academic skill (algorithm) to solve the problem. Spencer (2006) also 
found that mathematics achievement was especially impacted by CNS treatment (e.g. 
chemotherapy). 
 Neurophysiological Abnormalities.  
Neurophysiological abnormalities have been shown to occur in survivors of ALL. 
Ueberall et al. (1997) report that 53% of survivors of ALL have abnormal results on 
neurophysiological measures. Among survivors, individuals treated with both radiation 
and chemotherapy show the most neurophysiological abnormalities, followed by 
individuals treated with radiation only, followed by individuals treated with 
chemotherapy only (Hertzberg et al., 1997).  
Treatment for ALL, including chemotherapy, radiation therapy, and supplemental 
steroids may be associated with reduced cortical white matter volume, particularly in the 
right prefrontal cortex (Carey et al., 2008; Reddick et al., 2006). It is believed that 
reductions in white matter volumes as a result of treatment neurotoxicity contribute to 
observed declines in various domains of neurocognitive functioning, including speed of 
information processing and executive functions (e.g. planning, attention) (Carey et al., 
2008; Mulhern & Palmer, 2003). Reduced white matter volume is most severe in 
individuals who were treated with radiation in addition to chemotherapy (Porto et al., 
2008), however, significant white matter reduction is present in those treated only with 




investigated and directly correlated white matter reduction to reduce cognitive abilities in 
the areas of overall cognitive performance (Kesler, Tanaka, & Koovakattu, 2010), 
processing speed (Aukema et al., 2009), attention (Reddick et al., 2006), and working 
memory (Ashford et al., 2010). 
While white matter represents the most affected area of morphological changes in 
the brain of ALL survivors, some research indicates morphological changes in the frontal 
lobes and cerebellum. Some researchers theorize that acquired injuries in early childhood, 
like treatment for ALL, disrupt the developmental trajectory of neural growth and affect 
the frontal lobes and cerebellum in particular (Ciesielski, Harris, Hart, & Pabst, 1997; 
Horska et al., 2010; Lesnik, Ciesielski, Hart, Bensel, & Sanders, 1998). Results indicated 
that the most damage to these areas of the brain occurs when the insult occurs before age 
5, which is precisely when many individuals with ALL are diagnosed and begin 
treatment.  
Other neurophysiological (non-morphological) changes in the brain have been 
found, which may be precursors to cognitive late effects. There is evidence for impaired 
cerebral blood flow that occurs during treatment (Osterlundh et al., 1999). Additionally, 
biochemical changes that are precursors to brain damage have been found in the cerebro-
spinal fluid during induction chemotherapy (Osterlundh et al., 2008). These changes 
during chemotherapy may be precursors to changes in white matter and other brain areas 






  Working memory is the ability to temporarily store and cognitively manipulate 
information after a single presentation (Floyd, 2003). Verbal working memory 
(Baddeley, 1992) is activated when the presentation of information is heard, and visual 
working memory is activated when the presentation of information is seen. Working 
memory differs from other types of memory in that: 1) it manipulates incoming 
information and 2) the information dissipates within several seconds unless rehearsed 
(Towse, Hitch, & Hutton, 2000). 
 The most common theory of working memory was introduced by Baddely and 
Hitch in 1974. They outlined three components of working memory: the phonological 
loop, the visuospatial sketchpad, and the central executive. Recent revisions to this theory 
add a fourth component, the episodic buffer (e.g., Baddeley & Larsen, 2007). Working 
memory additionally accesses prior knowledge and long-term memory. This theory of 
working memory, as well as the existence of its components is well-supported by 
research (e.g., Baddeley et al., 1984; Baddeley & Hitch, 1994; Bishop & Robson, 1989). 
 The three main components of working memory work together to store and 
manipulate information. The central executive system supervises and controls the 
information that goes to and from the other components (phonological loop, visuospatial 
sketchpad, and episodic buffer). The phonological loop of working memory is activated 
by verbal and acoustic information. Once the information is heard, it enters a system that 




holds the information once it is presented verbally.  The visuospatial holds visually 
presented information (Baddeley, 2000). The newest proposed component of working 
memory, the episodic buffer, integrates incoming information (auditory and visual) with 
long term memory and semantic meaning (Baddeley, 2000).  
Recent revisions to this theory add a fourth component, the episodic buffer 
(Baddeley & Larsen, 2007). This revision proposes that working memory additionally 
accesses prior knowledge and long-term memory. The episodic buffer integrates 
incoming information (auditory and visual) with long term memory and semantic 
meaning (Baddeley, 2000).  
 A common measure of working memory is verbal presentation of a string of 
numbers that an individual needs to present in reverse order (Ackerman, Beier, & Boyle, 
2005). This particular task is present on many instruments that measure working memory 
in children (e.g., Woodcock-Johnson III, Weschler Intelligence Scale for Children, 
Fourth Edition, Differential Ability Scales, Second Edition, Test of Memory and 
Learning, Second Edition). For instance, on the Woodcock-Johnson III Tests of 
Cognitive Abilities (WJ-III Cog), the working memory cluster is comprised of 2 subtests: 
numbers reversed and auditory working memory. Numbers reversed is the task 
mentioned above, and auditory working memory is a task in which the subject hears 
works and numbers and repeats the words, then numbers in the order presented (Schrank, 
Flanagan, Woodcock, & Mascolo, 2002). Both tasks require that the subject manipulate 




that measure visual working memory. These subtests generally require the subject to 
watch the examiner manipulate objects in a particular sequence, and then the subject 
either repeats the sequence or performs it in the reverse order as was presented. A 
different way to measure visual working memory is to require the subject to look at a 
series of images, then manipulate them mentally (e.g. put in a different order, reverse the 
order).  
 Deficits in working memory can manifest in various parts of academic and every-
day life. Academically, working memory deficits seem to appear most clearly in 
mathematics performance, and most research linking working memory deficits to 
academic difficulties focus specifically on mathematics. 
  Many studies have shown that children who have specific math learning 
disorders (MLD) have concurrent deficits in working memory abilities. Strengths in 
mathematics ability has also been positively linked to working memory ability (Dark & 
Benbow, 1991). Geary et al. (1999) found that errors in mathematical problems (e.g. 
arithmetic, simple operations) that children with MLD make are due to insufficient 
working memory and executive functioning. Geary et al. (1999) concluded that executive 
functioning, especially working memory, contribute to mathematical deficits in children 
with MLD.  
Other studies have linked working memory to all children on certain 
mathematical tasks, such as story problems and mental addition (Adams & Hitch, 1997; 




to as story problems) are of particular interest to many researchers because of the 
seemingly complex nature of their presentation (whether oral or visual). In order to solve 
a math word problem, and individual not only has to read (or hear) and understand the 
problem, but convert the problem to mathematical terms, from which the problem can be 
solved. Executive processes, such as selective attention, are likely used to solve math 
word problems, which implicates the role of working memory as an important component 
in this process (Hale et al., 2003). Neuroimaging studies show that solving math word 
problems activates the frontal lobe, in particular Broca‟s area (Gruber, Indefrey, 
Steinmetz, & Kleinschmidt, 2001); the frontal lobe is responsible for executive processes 
and working memory, and Broca‟s area in particular is responsible for interpreting 
auditory information.  
While difficulties in mathematics are the most commonly seen and studied, other 
areas of academic achievement may be affected by working memory deficits as well. 
Difficulties with reading comprehension are connected to working memory difficulties 
(Caretti, Borella, Cornoldi, & De Beni, 2009). Both specific parts of working memory 
(e.g. attentional levels, auditory vs. visual working memory) and working memory levels 
in general are accurate predictors of difficulty with reading comprehension.  
A study conducted by Alloway (2009) determined that working memory levels 
predicted individuals with learning difficulties better than overall IQ. This indicates that 




with diminished working memory are significantly more likely to have academic 
difficulties.  
Gathercole (2008) described working memory deficits in the classroom, and 
determined that children with poor working memory skills show difficulty learning 
across academic subjects (reading, math, science, social studies, etc.) and that these 
deficits impact children in both primary and secondary grades. Gathercole describes 
academic difficulties due to working memory deficits as an overload on the working 
memory system, in which information is received by an individual with working memory 
deficits, but it is lost before it can be manipulated, leading to impaired achievement. 
Working memory is a complex, important cognitive skill, and is involved in other 
cognitive and neurological processes, including auditory processing and attention. 
Statement of the Problem 
 Recent improvements in the treatment of ALL have led to greatly increased 
survival rates; approximately 85% of children diagnosed with ALL will survive 5 years 
or more. Along with a greater number of survivors of ALL has come a greater incidence 
of late effects. Cognitive late effects, particularly with memory and attention, have been 
recently documented in survivors of ALL. However, since the greater incidence of 
survivors and discovery of cognitive late effects is a relatively recent phenomenon, all 
late effects in survivors of ALL have not been documented. Late effects in attention and 
memory have been well documented, but working memory, which is primarily comprised 




aimed to help fill this gap in the research. Specifically, this study investigated potential 
late effects on the specific cognitive ability of working memory.  
Research Questions and Hypotheses 
Research Question 1 
 Is working memory negatively impacted by the treatment of ALL in survivors of 
pediatric ALL? 
Hypothesis 1a. 
 It is expected that, when compared to their overall cognitive functioning as 
measured by psychometric intelligence, survivors of ALL will demonstrate significantly 
impaired working memory functioning. 
 Rationale 1a.  
Research has shown that the treatment of ALL potentially leads to cognitive late 
effects due to the toxicity of treatment (Hobbie et al., 2002; Weiner & Simone, 2003). 
Two of the most common late effects are deficits in memory and attention among 
individuals who received treatment for ALL (Askins & Moore, 2008; Cullen et al., 2002). 
Additionally, overall cognitive functioning is less impaired than specific abilities in 
individuals who received treatment. Given that both memory and attention are major 
components of working memory (Baddeley, 1992), it is expected that working memory 





 It is expected that, when compared to a normative sample, survivors of ALL will 
demonstrate significantly impaired working memory functioning. 
 Rationale 1b.  
Research has shown that both memory and attention are impaired in individuals 
who received treatment for ALL (Askins & Moore, 2008; Cullen et al., 2002). Given that 
both memory and attention are major components of working memory (Baddeley, 1992), 
it is expected that working memory will also be negatively affected when compared to 
normative controls.  
Research Question 2 
 Is there a difference in working memory functioning between male and female 
survivors of ALL? 
Hypothesis 2. 
 It is expected that females will perform significantly worse on measures of 
working memory than males. 
Rationale 2.  
Research has shown that females consistently display more severe cognitive late 
effects than males (Butler et al., 1999; Gamis & Nesbit, 1991; Leung et al., 2001; Palmer 




diagnosis and morbidity, females have more severe cognitive late effects, even when 
treatment is less intense (Raccione, 2002; Westlake & Bertolone, 2002). 
Research Question 3 
 In survivors of ALL, is there a difference between verbal and nonverbal working 
memory performance? 
Hypothesis 3. 
 It is expected that, in survivors of ALL, nonverbal working memory performance 
will be significantly worse than verbal working memory performance. 
 Rationale 3.  
Among late effects, general consensus dictates that nonverbal (e.g. spatial) 
performance is more severely impacted than verbal performance (Brown et al., 1998; 
Hobbie et al., 2002; Weiner & Simone, 2003). Nonverbal abilities include processing 





Chapter III: Method 
Participants 
Participants were 19 individuals ages 6 to 21 years who were designated as 
survivors of pediatric Acute Lymphoblastic Leukemia (ALL) by the LIVESTRONG 
Survivorship Center at Dell Children‟s Medical Center in Austin, Texas (hereafter 
referred to as LIVESTRONG). Patients were typically designated as survivors once they 
have completed treatment and are cancer-free for roughly one year. The following 
inclusion criteria applied: Participants must be (a) post-treatment and in survivorship for 
pediatric ALL, (b) between 6 and 21 years of age, and (c) English-speaking. Individuals 
meeting school criteria as having a visual or auditory impairment were not included as 
participants in this study. Additionally, individuals who were undergoing treatment for 
ALL at the time of the study, who underwent a bone-marrow transplant, had a recurrence 
of cancer, or who had impaired global cognitive functioning (e.g. mental retardation) 
were not included in this investigation. 
Instrumentation 
Wechsler Abbreviated Scale of Intelligence.  
 The Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999) is a 
brief, reliable measure of intelligence that can be used with individuals ages 6-89 years. It 
is comprised of four subtests that are parallel to subtests found on the more detailed 




Wechsler Adult Intelligence Scale, 4rd Edition). Intended use of the WASI includes brief 
assessment of an individual‟s overall level of cognitive functioning. Administration 
requires approximately 30 to 45 minutes. The WASI contains four subtests; two of the 
subtests measure verbal performance (Vocabulary, Similarities) and two of the subtests 
measure nonverbal performance (Block Design, Matrix Reasoning).  Vocabulary requires 
the child to define orally and graphically presented words. The Similarities subtest 
requires the child to answer questions about how two objects or concepts are alike. Block 
Design requires the child to reproduce designs quickly using blocks. Matrix Reasoning 
requires the child to determine a piece of a missing visual matrix from an array of answer 
choices (Sattler & Dumont, 2004). All four subtests were administered in this study to 
obtain an estimate of verbal functioning (VIQ), nonverbal/visual-spatial functioning 
(PIQ) and overall psychometric intelligence (FSIQ). The WASI was normed according to 
the 1997 census data. The normative sample included 2, 245 children and adults which 
was stratified based on geographic region, age, sex, ethnicity, and education level. The 
WASI demonstrates adequate reliability across both children (ages 6-16) and adults (ages 
17-89). For children, the reliability for the IQ score ranges from .92 to .95, and for adults 
ranges from .96 to .98. 
Wechsler Intelligence Scale for Children - Fourth Edition.  
 The Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV; 
Wechsler, 2003) is an individually administered instrument used to assess psychometric 




standardization samples which represent the United States population based on the March 
2000 census. The normative sample was stratified based on age, sex, race, parent 
education level, and geographic region (Wechsler, 2003). Although the WISC-IV 
contains 15 subtests, only one subtest was used in this study. The Digit Span subtest, 
which is used to measure an individual‟s working memory, was administered. This 
subtest required the child to listen to and repeat strings of numbers, both in forward and 
reverse order (Sattler & Dumont, 2004). This subtest has two portions: digit span forward 
and digit span backward. A process score was derived for each child‟s digit span 
backward (DSB) because this portion of the subtest is a better estimate of working 
memory than digit span forward. The process score was derived using the raw score of 
the DSB portion of the subtest and was translated using table A.8 in the WISC-IV scoring 
manual (Wechsler, 2003). The Digit Span subtest is a reliable measure, having the 
following reliabilities: Internal Consistency: .87; Test-Retest Reliability: .81. The process 
scores display strong reliability was well, ranging from .72 to .82 across ages 6 to 16. 
Test of Memory and Learning, Second Edition.  
 The Test of Memory and Learning, Second Edition (TOMAL-2; Reynolds & 
Voress, 2007) is a standardized battery used to measure different memory functions in 
individuals ages 5 to 59 years. The TOMAL-2 was normed using a standardization 
sample of 1,961 individuals residing in 28 states. The sample was stratified based on the 
2002 census and the following demographic characteristics were considered: gender, 




status, and age (Reynolds & Voress, 2007). The TOMAL-2 includes 8 core subtests and 6 
supplementary subtests; however, this study only used 2 subtests: Visual Sequential 
Memory and Letters Backward. These subtests provided estimates of verbal and 
nonverbal working memory. Visual Sequential Memory required the examinee to recall a 
sequence of designs in a particular order. Letters Backward required the examinee to 
recall a string of letters in reverse order. Adequate reliability is present for both subtests. 
Visual Sequential Memory reliability estimates range from .78 to .92 for ages 6-18. 
Letters Backward reliability estimates range from .87 to .98 for ages 6-18. 
Procedure 
Approval by Human Subjects Committee. 
 This study complied with ethical standards posed by the American Psychological 
Association, the University of Texas at Austin, and Seton Family of Hospitals. On 
December 17, 2009, the Departmental Review Committee of the Department of 
Educational Psychology and the Institutional Review Board approved the study. 
Parents/guardians of each child participant signed an IRB-approved consent form and 
each child participant signed a form of assent. The consent form can be found in 
Appendix A and the assent form can be found in Appendix B. 
Recruitment of Participants. 
 Participants were recruited through the LIVESTRONG center in Austin, Texas. 




who met the inclusion criteria were invited to participate in the study.  Participants were 
identified and attained through LIVESTRONG in one of two ways. Participants were 
either (1) individuals who were newly identified by a LIVESTRONG oncologist as 
meeting survivorship criteria (hereafter referred to as a New Survivor) or (2) individuals 
who were previously identified by a LIVESTRONG oncologist as meeting survivorship 
criteria and were scheduled for an annual follow-up meeting (hereafter referred to as 
Follow-Up Survivor). New Survivors were referred for neuropsychological evaluation by 
their LIVESTRONG pediatric oncologist as a component of their direct survivorship 
services, whereas Follow-Up Survivors were recruited prior to their annual 
LIVESTRONG checkup and neuropsychological reevaluation. New and Follow-Up 
Survivors were invited to participate in the current study in which they received a full 
neuropsychological evaluation, integrated report, and feedback at no charge in exchange 
for their consent and assent. 
Once identified as meeting criteria for the study, the guardians of potential 
participants (or participants if age 18 or older) were provided with a flyer that gave a 
brief description of the study, primary investigator contact information, and space for the 
individual to provide contact information. The potential participants, or their guardian, 
were asked to return the flyer using a pre-paid envelope or in person. In total, 65 
individuals were identified through LIVESTRONG that met study criteria and were 
subsequently given study flyers. Of these 65 individuals, 25 returned flyers to the primary 
investigators. Three individuals declined to participate or were non-responsive to the 




and one child died before she could participate in the study. One child was excluded due 
to radiation during treatment for cancer; this information was discovered following the 
neuropsychological evaluation and his data was forthwith removed. Therefore, the total 
number of participants in the study amounted to 19 individuals. 
Data Collection. 
            Children whose parents gave consent to participate and met inclusion criteria and 
young adults (ages 18-21) who gave consent and met inclusion criteria were participants 
of this study. Once consent was given, the parent or guardian of the child scheduled an 
appointment with the principal investigator for the child to participate in a full 
neuropsychological evaluation. The evaluation took place in a quiet, private room in the 
Children‟s Blood and Cancer Center in the Specially for Children building at Dell 
Children‟s Hospital in Austin, Texas. The child engaged in a one-on-one 
neuropsychological evaluation with the principal investigator for approximately 120-150 
minutes while the parent/guardian waited in a waiting area and filled out parent forms. 
The child was allowed take breaks as needed during testing.  
The neuropsychological evaluation provided estimates of each participant‟s 
psychometric intelligence, verbal performance, nonverbal performance, academic 
achievement, short-term memory, delayed memory, working memory, processing speed, 
executive function, and emotional functioning. Although this study only used data from 
three instruments, other measures were used for the purpose of the evaluation. These 




subtests), Test of Memory and Learning, Second Edition (TOMAL-2; selected subtests), 
Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV; selected subtests), 
Differential Ability Scales, Second Edition (DAS-II; selected subtests), Halstead-Reitan 
Battery (selected subtests), Controlled Oral Word Association Test (COWAT), Behavior 
Rating Inventory of Executive Function (BRIEF; parent and teacher forms), Trail Making 
Test, and Behavior Assessment Scale for Children, Second Edition (BASC-2;parent, self, 
and structured developmental history forms). 
            The parent gave teacher forms to the participant‟s teacher, who, when consent 
was given, filled out and mailed the form in a self addressed, stamped envelope, back to 
the investigator. Upon completion of each evaluation, the principal investigator scored 
each measure and wrote an integrated report which included summaries of the child‟s 
neuropsychological functioning, implications for school and home functioning, and 
recommendations. The principal investigator was supervised by a Ph.D. level licensed 
neuropsychologist. When each report was complete, the parent/guardian was given the 
option of receiving feedback over the phone summarizing the results of the evaluation. 
Then, the parent/guardian received a copy of the report which the parent used as he/she 
wished. 
Calculation of Composites. 
Composite scores were used in the analyses in this study and were computed by 
transforming measures from standard and scaled scores to z-scores and then averaging the 




(WMC) was determined by converting the individual‟s scores from Digit Span Backward 
(DSB), Letters Backward (LB), and Visual Sequential Memory (VSM) to z-scores. The 
three z-scores were then averaged, comprising the WMC. The Verbal Working Memory 
Composite (VWMC) was calculated in a similar manner by converting the individual‟s 
scores from Digit Span Backward (DSB) and Letters Backward to z-scores and averaging 
the two scores. The Nonverbal Working Memory Composite (NVWMC) was calculated 
by converting the individual‟s score on Visual Sequential Memory to z-scores. All z-




Chapter IV: Results and Analyses 
This investigation was conducted to further research regarding working memory 
abilities in survivors of pediatric acute lymphoblastic leukemia who were treated with 
chemotherapy alone. Working memory performance was compared to the sample‟s mean 
cognitive abilities as well as the population‟s average performance. Additional 
comparisons of working memory performance in males versus females and verbal versus 
nonverbal working memory were analyzed. Power analysis indicated low power to find 
statistically significant results, so qualitative and supplementary analyses were conducted 
in addition to quantitative analyses. All statistical analyses were performed using SPSS 
(version 17.0).  
Preliminary Data Analyses 
Descriptive Statistics. 
Means, standard deviations, and ranges for Full Scale IQ (FSIQ) and all subtests 
are reported in Table 1.  As shown in Table 1, the sample‟s mean FSIQ was slightly 
higher than the population‟s FSIQ of 100. The Digits Reversed Process Score mean for 
the sample was below the population‟s mean of 10 and both the Letters Backward and 
Visual Sequential Memory means are slightly larger than the population mean of 10. 
Other descriptive statistics can be found in appendices C through F and intercorrelations 
between variables can be found in Appendix G. The descriptive statistics were calculated 





Descriptive Statistics of Variables 
 








72 – 129 
Digit Span Backwardb            8.74            2.45           5 – 13 
Letters Backwardc           10.32            3.71           4 – 20 
Visual Sequential Memoryc 10.47 2.29 7 - 15 
 
aAs measured by the WASI; Standard score. 
bProcess score as measured by the WISC-IV/WAIS-IV; Scaled score. 
cAs measured by the TOMAL-2; Scaled score. 
 
Assumptions of t-tests. 
The data were examined for violation of assumptions required for t-tests. In order 
to accurately analyze data using t-tests, all variables must conform to the normality 
assumption (Urdan, 2010) which assumes that the data for each variable are normally 
distributed.  The Kolmogorov-Smirnov Test of Normality was completed using SPSS 
version 17.0 and the following variables had a non-normal distribution: Letters Backward 
(LB), Working Memory Composite (WMC), and Verbal Working Memory Composite 
(VWMC). Upon further inspection, LB had a non-normal distribution with a positive 
skew. Since LB is part of both the WMC and VWMC composites, and both of the 
remaining variables comprising the composite were normally distributed (Digit Span 
Backward and Visual Sequential Memory), LB was modified using a Log10 
transformation (Field, 2009). The Log10 transformation successfully resolved the 




recalculated using these new values, all variables met the normality assumption for t-
tests.  
Power Analysis 
Power is the ability to correctly reject a false null hypothesis when using 
statistical analyses. It relies on the effect size, alpha level, and sample size (Keith, 2006). 
Power analysis was conducted using GPower (version 3.0; Faul, Erdfelder, Lang, & 
Buchner, 2007) in order to determine the necessary sample size to detect significance 
using t-tests. Adequate power was not obtained for the available sample (19 participants). 
For the various effect sizes and analyses for the hypotheses, power levels with a medium 
effect size ranged from 0.14 - 0.32, meaning that given a medium effect size, there would 
be only a 14-32% chance of rejecting a false null hypothesis. Since power levels of 0.80 
and higher are considered adequate to find statistically significant results, the available 
power for this study‟s available sample was much lower than desired. In order to obtain 
adequate power (0.80) with a medium effect size, the necessary sample size would be N =  
34. Therefore, qualitative analyses were conducted in addition to statistical analyses (t-
tests) to provide a clearer picture of the data and its trends.   
Main Analyses 
 For each hypothesis, several types of analyses were conducted. First, quantitative 
analyses were conducted for each hypothesis. Next, qualitative analyses for each 
hypothesis were conducted as well, given concerns about power levels. Supplemental 




analyses will be presented in the following order: Quantitative analyses, qualitative 
analyses, supplemental analyses. 
Quantitative Analyses. 
Hypothesis 1a. 
It is expected that, when compared to overall cognitive functioning as measured 
by psychometric intelligence, survivors of Acute Lymphoblastic Leukemia (ALL) will 
demonstrate significantly impaired working memory functioning. 
A paired-sample t-test was conducted to determine whether the Working Memory 
Composite (WMC) was significantly lower than the Full Scale IQ (FSIQ) for this sample. 
There was no significant difference in scores between FSIQ (M = 0.4279, SD = 1.0658) 
and WMC (M =-0.0879, SD = 1.7123; t (18) = 1.719, p = 0.103 (two-tailed)). However, 
the magnitude of the differences in the means (mean difference = 0.51582, 95% CI: -.11 
to 1.15) was large (eta squared = 0.141). 
Hypothesis 1b. 
It is expected that, when compared to a normative sample, survivors of Acute 
Lymphoblastic Leukemia (ALL) will demonstrate significantly impaired working 
memory functioning. 
A paired-sample t-test was conducted to determine whether the Working Memory 
Composite (WMC) was significantly lower than the mean Full Scale IQ (FSIQ) for the 




(M =-0.0879, SD = 1.7123; t (18) = 0.224, p  = 0.825 (two-tailed)) was not significant. 
Additionally, the magnitude of the differences in the means (mean difference = 0.0879, 
95% CI: -0.74 to 0.91) was small (eta squared = 0.0028). 
Hypothesis 2. 
It is expected that females will perform significantly worse on measures of 
working memory than males. 
Given the abnormal distribution of males and females in the sample, t–tests could 
not be calculated for this hypothesis. In lieu of an independent sample t-test, the Mann-
Whitney U test (a non-parametric test of differences between two independent groups on 
a continuous measure) was calculated. A Mann-Whitney U test revealed no significant 
difference in the Working Memory Composites (WMC) between males (Md = -0.19, n = 
14) and females (Md = -0.76, n = 5; U = 29, z = -0.556, p = 0.578). The effect size (r = 
0.1276) was small. 
Hypothesis 3. 
It is expected that, in survivors of Acute Lymphoblastic Leukemia (ALL), 
nonverbal working memory performance will be significantly worse than verbal working 
memory performance. 
A paired-sample t-test was conducted to determine whether the Verbal Working 
Memory Composite (VWMC) was significantly lower than the Nonverbal Working 




scores between VWMC (M = -0.2111, SD = 2.3691) and NVWMC (M = 0.1584, SD 
=0.7646; t (18) = -0.757, p  =  0.459 (two-tailed)). The effect size of the differences in the 
means (mean difference = -0.3695, 95% CI: -0.37 to 0.66) was small (eta squared = 
0.03). In addition, the relationship between verbal and nonverbal WMC was the opposite 
of the relation hypothesized, as the nonverbal composite was higher than the verbal 
composite. 
Qualitative Analyses. 
Hypothesis 1a: Working memory compared to sample IQ. 
Qualitative analysis for Hypothesis 1a was tested by comparing each individual‟s 
Working Memory Composite (WMC) score to his or her Full Scale IQ (FSIQ) as 
determined by the Wechsler Abbreviated Scale of Intelligence (WASI). Each individual‟s 
difference score between FSIQ and WMC was computed, and a difference score of z =-
1.0, or WMC being one standard deviation below FSIQ, was considered clinically 
significant. The value 1.0 was chosen as the significant value because a difference of this 
size would be considered significant in the clinical setting. If a child‟s working memory 
skills are 1 SD below his or her overall cognitive functioning, it would be considered a 
personal weakness. 
 The overall mean difference between the participants‟ FSIQ and WMC was z = 
0.4758, which is not clinically significant. However, upon individual analysis, 6 of 19 
participants displayed significantly lower WMCs than FSIQ, and 15 participants‟ WMC 




Figure 1 shows each participant‟s WMC and FSIQ comparisons, displaying how the 
majority of WMC scores were below FSIQ. While qualitative analyses did not produce 
clinically significant outcomes for hypothesis 1a, the results were in the expected 
direction. 
Figure 1: FSIQ versus WMC 
  
                     Subjects; N = 19   
 
Hypothesis 1b: Working memory compared to population IQ. 
Qualitative analysis for hypothesis 1b was tested by comparing each individual‟s 
Working Memory Composite (WMC) to the normative Full Scale IQ (FSIQ) mean of z = 
0. The overall mean difference between the normative mean FSIQ and WMC was z = -
.479, which is not clinically significant. Upon individual analysis, only 1 of 19 






was below normative mean FSIQ. The greatest difference was z = -1.11. While 
qualitative analyses do not produce clinically significant outcomes for hypothesis 1b, 
again, the results were in the expected direction.  
 Hypothesis 2: Gender differences. 
Hypothesis 2 was tested by comparing the Working Memory Composites (WMC) 
of male participants to the WMCs of female participants. Again, z = 1.0 was chosen as 
the significant value because a difference of this size would be considered significant in 
the clinical setting. The mean difference between male and female WMC was z = 0.1494, 
which is not significant. 
Hypothesis 3: Verbal versus nonverbal working memory. 
Hypothesis 3 was tested by comparing the mean Verbal Working Memory 
Composite (VWMC) to the mean Nonverbal Working Memory Composite (NVWMC). 
A difference score of greater than z = 1.0 was considered clinically significant. 
The overall difference between the VWMC and NVWMC was z = 0.2742, which 
is not clinically significant. Additionally, the mean NVWMC was positive and the mean 
VWMC was negative, which was the reverse of what was expected.  
Supplemental Analyses. 
According to Reynolds (1997), composite scores may mask the effects of the 
individual scales that comprise a composite score. To investigate whether the Working 




accurate representations of the subscales that comprise them, post-hoc analyses were 
conducted using measures individually instead of the composite. 
Hypothesis 1a: Working memory compared to sample IQ. 
In addition to the paired-sample t-test comparing the Working Memory 
Composite (WMC) to Full Scale IQ (FSIQ), each subtest contributing to the WMC was 
also compared to the sample‟s FSIQ. A paired-samples t-test was conducted to compare 
the Digit Span Backward process scores to the FSIQ. There was a significant difference 
between the two scores (Digit Span Backward: M = -0.4221, SD = 0.8159; t (18) = 3.173, 
p  =  0.005 (two-tailed)). The paired samples t-test comparing FSIQ to Visual Sequential 
Memory was not significant (Visual Sequential Memory (M = 0.1584, SD = 0.7646; t 
(18) = 1.225, p  =  0.236 (two-tailed)). There was no significant difference in scores when 
comparing the FSIQ to Letters Backward (Log10 transformation; Letters Backward 
Log10: M = -0.0001 , SD = ;4.3594 t (18) = 0.493, p  = 0.628  (two-tailed)).  
Hypothesis 1b: Working memory compared to population IQ.  
Individual paired-sample t-tests were run comparing each individual Working 
Memory Composite (WMC) subtest to the population Full Scale IQ (FSIQ) of z = 0. A 
paired-samples t-test was conducted to compare the Digit Span Backward process scores 
to the population FSIQ. There was a significant difference between the two scores (t (18) 
= 2.255, p  =  0.037 (two-tailed)). The paired samples t-test comparing FSIQ to Visual 




0.378 (two-tailed)). There was no significant difference in scores when comparing the 
FSIQ to Letters Backward (t (18) = 0.000, p  = 1.000  (two-tailed)). 
Hypothesis 3: Verbal versus nonverbal working memory. 
Individual paired-sample t-tests were run comparing each individual Verbal 
Working Memory Composite (VWMC) subtests to the Nonverbal Working Memory 
Composite (NVWMC; comprised of a single score: Visual Sequential Memory). A 
paired-samples t-test was conducted to compare the Digit Span Backward (DSB) process 
score to the NVWMC score. There was a significant difference between the two scores (t 
(18) = -2.762, p  =  0.013 (two-tailed)) with DSB being significantly lower than VSM. 
The paired samples t-test comparing Letters Backward (with Log10 transformation; LB) 
to VSM was not significant ((t (18) = 0.117, p  =  0.908 (two-tailed)).  
Summary 
Hypothesis 1a, which predicted that the sample‟s working memory would be 
below the sample‟s IQ was not confirmed with either quantitative (t-test) or qualitative 
methods. Upon supplemental analysis, the individual subtest Digit Span Backwards 
(DSB) was found to be significantly lower than the sample‟s IQ, but the other working 
memory subtests, Letters Backward (LB) and Visual Sequential Memory (VSM) were 
not significantly below IQ. Hypothesis 1b predicted that the sample‟s working memory 
would be below the population‟s mean IQ. Like hypothesis 1a, neither quantitative nor 
qualitative analyses yielded significant results, but supplemental analyses revealed that 




below IQ). Hypothesis 2 predicted that females would perform worse than males on 
measures of working memory. This hypothesis was not confirmed with quantitative or 
qualitative methods. Lastly, hypothesis 3, which expected that within the sample, 
nonverbal working memory would be significantly worse than verbal working memory, 
was not confirmed by either quantitative or qualitative methods. Additionally, upon 
supplementary analysis, DSB was found to be significantly below VSM, the nonverbal 
working memory subtest, and LB was not significantly different from VSM. The results 




Chapter V: Discussion 
 This study aimed to expand the research base for working memory late effects in 
survivors of pediatric Acute Lymphoblastic Leukemia (ALL), an understudied area in 
cancer survivorship. Working memory is an important cognitive ability that is heavily 
involved in the successful performance of many academic and daily-living activities. 
Specifically, this study investigated working memory ability in survivors of ALL as 
compared to overall cognitive ability, the effect of gender on working memory, and 
differences between verbal and nonverbal working memory. It was expected that, in 
survivors of ALL, working memory would be less developed than overall cognitive 
functioning, that females would perform worse than males on measures of working 
memory, and that nonverbal working memory would be less developed than verbal 
working memory. These hypotheses were generated based on previous research that 
confirmed the existence of attention and memory deficits, poorer female performance, 
and poorer performance on nonverbal tasks in survivors of ALL. Results for all tests of 
the current data were nonsignificant, indicating that working memory and overall 
cognitive ability were comparable, as was performance between males and females, and 
performance between verbal and nonverbal working memory tasks. However, 
supplemental analyses revealed an interesting and significant finding, that performance 
on the specific working memory subtest Digit Span Backward (DSB), a verbal working 
memory task, was significantly lower than overall cognitive ability and nonverbal 
working memory. The largely nonsignificant findings and the meaning of this important 





 In this study, none of the hypotheses were confirmed as all main analyses resulted 
in nonsignificant results. An obvious explanation for these results may be that working 
memory is not impaired in survivors of ALL who were treated solely with chemotherapy. 
This explanation goes against the previous literature that cites the importance of attention 
and memory in the successful utilization of working memory and cancer literature that 
confirms late effects in attention and memory, even in individuals treated with 
chemotherapy alone. So how could this be? 
 One potential explanation for the nonsignificant results is that, since ALL is 
typically diagnosed at a very young age (~ 3 years), the brain develops in a way that is 
resilient and spares working memory. Since development of higher order executive 
functions does not occur until later in childhood (~7 years), the young brain that is 
affected by treatment for cancer may develop atypical pathways that nevertheless result 
in intact working memory skills.  
 Another explanation may be that, since working memory is not governed by a 
single brain structure, but rather by multiple structures and pathways, damage done by 
chemotherapy may not be significant enough to disrupt the entire system of working 
memory. While memory and attention are frequently damaged in survivors of ALL, it 
may be that the damage to these two components of working memory is not enough to 
impart detrimental effects on the working memory system. 
While the lack of significant findings does not lead to an interesting discussion of 




survivors of ALL. However, this conclusion may be premature and studies investigating 
working memory in survivors of ALL treated with chemotherapy alone should not yet be 
dismissed. Supplemental analyses highlighting the importance of a specific working 
memory test and methodological limitations of this particular study are discussed next, as 
they give reason to continue studying this important cognitive ability in chemotherapy-
treated survivors of ALL. 
Working Memory in Survivors of ALL  
Recent treatments for ALL have proven to be very effective at eliminating cancer, 
but they leave behind a variety of detrimental effects, many of which manifest long after 
treatment is terminated. These “late effects” of treatment have been found to have an 
influence on many areas of cognition, including memory and attention, which in turn 
negatively impact academic and daily-living skills. This study focused on working 
memory (which relies heavily on both attention and memory and is essential in the 
successful performance of many tasks), asking the question as to whether it is actually 
impaired in survivors of Acute Lymphoblastic Leukemia (ALL). In an attempt to answer 
this question, working memory skills were compared to overall cognitive functioning 
(IQ), to determine if the ability was specifically impaired. Reasonable estimates of 
working memory and IQ were obtained. As determined by main qualitative and 
quantitative analyses, no significant differences between working memory and IQ were 
found. However, in performing specific supplemental analyses and looking at effect size 




The main analyses used a working memory composite (WMC) to estimate 
working memory ability, which was the average of performance on three individual tasks 
measuring working memory. Using the WMC, no significant differences were found 
between working memory and the sample or population IQ. Likewise, when using a 
verbal working memory composite (VWMC) compared to a nonverbal working memory 
task (Nonverbal Working Memory Composite, NVWMC), no significant differences 
were found. These results were unexpected, but in working to better understand the 
nature of composites, it was learned that composite scores, such as the ones used for this 
study, may “wash out” the effects of the individual scores that comprise them (Reynolds, 
1997). Therefore, supplemental analyses were conducted to determine if individual 
differences between task and IQ (Hypothesis 1a and 1b) and verbal and nonverbal 
working memory tasks (Hypothesis 3) existed.  
 Among the subtests comprising the WMC, one stood out in supplemental 
analyses: Digit Span Backward from the Wechsler Intelligence Scale for Children, Fourth 
Edition (DSB; WISC-IV; Wechsler, 2003). DSB was significantly lower than the 
sample‟s IQ, the population‟s IQ, and the Visual Sequential Memory subtest from the 
Test of Memory and Learning, Second Edition (VSM; TOMAL-2; Reynolds & Voress, 
2007). When compared outside of the composite, performance on this subtest (DSB), 
which represents the most commonly used type of working memory task in evaluations 
(Ackerman et al., 2005), was significantly lower than cognitive and other working 
memory performance. This appears to be a unique finding to this study, as it does not 




 An interesting question is: Why is Digit Span Backward so different? What is it 
about this particular task that makes it significantly more difficult than other working 
memory tasks? When the working memory tasks from the TOMAL-2, Letters Backward 
(LB) and VSM, were compared to IQ, there were no significant differences, indicating a 
potential difference in either the task of DSB, or possibly the norms from which scores 
are derived.  
As DSB and LB are compared, the main distinction appears to be the difference 
between having to listen to numbers and then repeat them in reverse order (DSB) versus 
listening to letters and repeating them in reverse order (LB). While the examinee is 
required to perform very similar tasks on these subtests, the methods of scoring the items 
are different. DSB requires the examinee to repeat all digits in the reverse order to receive 
credit, whereas LB accepts all letters that are recited in the proper place as correct. For 
example, on DSB, if an individual switches the location of two numbers in a response, 
the entire response is incorrect, even if all other numbers are correctly located. On LB, if 
an individual makes the error of switching two letters in a response but all other letters 
are in the proper place, partial credit for the item is given. Therefore, if an individual 
responds with inaccurate manipulation of information, decay of information, or both, he 
may still earn credit on LB, but not on DSB.  
 When comparing DSB to VSM, there are many observable differences, as DSB is 
a verbal working memory task whereas VSM is a visual working memory task. DSB 
requires the examinee to listen to the stimuli and then manipulate it without any aids (e.g. 




designs in a particular order, then look at the same designs in a different order. The initial 
stimuli are shown twice, removing some exertion on the immediate memory. The 
examinee must then point to the designs in the order initially presented. Like LB, VSM 
allows credit on all correctly sequenced stimuli, so the examinee need not display perfect 
performance on items to receive credit. Face value of comparing these tasks indicates that 
DSB may place more strain on the working memory system than VSM because DSB 
requires both complete and accurate memory of the stimuli and precise manipulation. 
While VSM also requires memory of the stimuli, the stimuli is re-introduced during each 
item, potentially allowing a memory boost for decayed information and  total accuracy is 
not essential for item credit. 
 Thus, when comparing DSB to both LB and VSM, DSB may impart the greatest 
load on working memory. Both LB and VSM allow room for error and VSM also 
provides re-introduction of the stimuli. These differences may account for DSB scores 
being significantly lower than IQ and visual working memory. When approached with 
the understanding that DSB may be a more stringent and pure estimate of working 
memory, it provides support for the notion that working memory may be impaired in this 
study‟s population (survivors of pediatric ALL). 
 Since DSB is a subtest from the WISC-IV and LB and VSM are subtests from the 
TOMAL-2, a comparison of norms and reliability must also be considered. The 
normative sample of the WISC-IV is slightly greater than that of the TOMAL-2, with 
2200 individuals from all states in the United States compared to 1961 individuals from 




socioeconomic status, parent level of education, geographic region, exceptionality status, 
and age were effectively correlated with the US census data, indicating a representative 
sample (Reynolds & Voress, 2007; Wechsler, 2003). Additionally, reliability estimates 
for all three subtests were strong. Therefore, the difference in DSB is not likely 
contributable to differences in norms or reliability.  
In addition to comparing working memory to overall cognitive abilities, this study 
also aimed to compare verbal and nonverbal working memory, expecting nonverbal 
memory to be less well developed. As mentioned previously, supplemental analyses 
revealed that performance on Digit Span Backward (DSB) was significantly lower than 
Visual Sequential Memory (VSM). This pattern of performance is the opposite of what 
was expected, given that DSB is a verbal task and VSM is a nonverbal task. This 
unexpected finding is unique to this study and has not been found or investigated 
elsewhere and could be a result of several different explanations. This finding may reflect 
a true difference between verbal and nonverbal working memory in survivors of ALL. If 
this reason holds, it may be that nonverbal working memory differs from other nonverbal 
tasks in survivors of ALL in such a way that nonverbal working memory is unimpaired 
by late effects. Another possibility is that this pattern of working memory functioning 
holds in the general population and is non-specific to survivors of ALL, indicating no 
unique working memory problems in the study‟s population. A third consideration, as 
previously discussed, is that this finding may be a reflection of measurement issues 




of working memory. While this hypothesis resulted in unexpected findings, the overall 
significance of DSB links with previous research in several areas. 
 If working memory is indeed part of the myriad of late effects that are found in 
survivors of ALL, previous research would support this finding in several ways. First, if 
working memory is impaired in survivors of ALL, even to a slight degree, it would align 
with previous literature in several areas. This finding is consistent with literature 
indicating that white matter damage, particularly in the right prefrontal cortex, may be the 
mechanism responsible for many cognitive late effects (Carey et al., 2008; Reddick et al., 
2006). Since individuals exposed to chemotherapy lose white matter, particularly in the 
brain region responsible for many executive functions, it makes sense that working 
memory, a complex and integrative skill that is important to executive function, could 
potentially become impaired.  
Negatively affected working memory is also consistent with models of working 
memory that purport the importance of memory and attention. Since memory and 
attention have been shown to be very sensitive to late effects (e.g. Ashford et al., 2010; 
Askins & Moore, 2008; Reddick et al., 2006; Spencer, 2006) and are vital to working 
memory performance (Baddeley et al., 1984; Baddeley & Hitch, 1994; Bishop & Robson, 
1989), the finding of poor Digit Span Backward performance is consistent with this 
literature and model.  
Poor performance on DSB is also consistent with previous research that indicates 
specific deficits in mathematics (Brown et al., 1992). The skills required to perform well 




require accurate mental manipulation of numbers. Previous research confirms working 
memory‟s importance in mathematics (Adams & Hitch, 1997; Gruber et al., 2001). This 
strong link between working memory and mathematics implies that survivors of ALL 
may benefit from specific modifications, particularly in the area of mathematics, to 
perform at age and grade expected levels. 
In summary, Digit Span Backward (DSB) was significantly impaired whereas 
other working memory tests were not impaired in survivors of ALL treated with 
chemotherapy alone. Upon examination of the individual working memory tasks, DSB 
was found to be unique in several ways, and was determined to be the most sensitive and 
“pure” measure of working memory. Working memory is understudied in pediatric 
cancer survivorship literature and has not yet been identified as an area impacted by late 
effects of treatment. However, this unique finding that DSB is significantly lower than IQ 
and other working memory tasks implies that, in contrast of nonsignificant results of 
main analyses in this study, working memory, as measured by a sensitive test, may be an 
important part of the constellation of late effects that affect survivors of ALL. 
Effect Size and Trends of Working Memory Performance 
 Effect size and directionality of data were considered in addition to formal 
hypothesis testing to contribute additional understanding of the data. Effect size is 
another way to quantify the extent of the difference between groups (Urdan, 2010). The 
effect size essentially estimates the magnitude of the relationship, independent from 
determining if the mean differences are great enough to be significant (t-tests in this 




the IQ in survivors of pediatric ALL (Hypothesis 1a), and while statistical significance 
was not found, the effect size was large. This large effect size provides evidence in 
support of the hypothesis that working memory is impaired in survivors of ALL.   
Although qualitative and quantitative analyses did not confirm a significant 
difference between working memory and sample IQ, the large effect size confirmed that 
there was, indeed, a strong relationship between working memory and IQ. 
In contrast, when working memory was compared to the population‟s IQ (Hypothesis 
1B), the effect size was small, indicating a weak relationship between working memory 
and population IQ. The difference in the effect sizes between these two hypotheses (1a: 
working memory versus sample IQ; 1b: working memory versus population IQ) may be 
explained by the finding that, in the sample population, IQ was four standard score points 
higher than the overall population IQ (Sample IQ: 104; Population IQ: 100). Therefore, 
when comparing the same estimate of working memory, the difference between working 
memory and the sample IQ was larger than the difference between working memory and 
the population IQ.  
 As stated previously, the difference between working memory and IQ in this 
population was not great enough to yield statistical significance. Qualitative methods did 
not produce evidence of clinical significance either. However, upon further examination 
of qualitative data, an interesting clinical picture appeared. Most participants‟ working 
memory performance was lower than his or her IQ (15 of 19; 79% of participants) and 
over half of the sample‟s working memory performance was lower than the sample IQ 




poorer performance on working memory tasks than on other cognitive tasks, particularly 
among intraindividual comparisons, held across most participants. This pattern may 
indicate milder deficits in working memory that could nevertheless impact functioning. 
For instance, parents or teachers may expect a child who displays above average overall 
intelligence to be able to keep up with difficult mental arithmetic and orally-administered 
directions. However, if the child has even mild working memory problems, he or she may 
not be able to perform as well on working-memory heavy tasks. In this way, even though 
the deficit is small, it may have functional implications.  
 The findings of poorer performance on DSB and the large effect size between 
working memory and IQ provide evidence in support of the value of continued research 
and investigation of working memory in survivors of ALL. Additionally, the limitations 
of this particular study are vital to review, as the results must be understood within the 
context of the study‟s restrictions.  
Nonsignificant Effect of Gender 
 In addition to investigating the effects of working memory for the entire sample, 
gender was independently analyzed. Literature in late effects has reported that overall, 
female pediatric cancer survivors tend to exhibit more exaggerated late effects than their 
male counterparts (Peterson et al., 2008). Thus, it was hypothesized that this pattern 
would hold true for this study‟s population when comparing working memory ability. 
However, analysis from this study indicated that no gender differences existed for the 
sample. It is possible that the disproportionate number of males to females may have 




rate (14 males, 5 females). It is also possible that working memory is neither impaired 
nor different between male and female survivors of ALL treated with chemotherapy.  
Limitations  
 Given the available sample and resources, there are several important limitations 
of this study. As previously addressed, the sample size was small which led to decreased 
power to find significant differences in addition to restricted methods of statistical 
analysis. This is an important limitation to understand, as it affected the effectiveness of 
statistical analyses to provide accurate information about the “true” nature of the sample. 
As such, the statistical results of this study do need to be interpreted with caution and 
would be best if re-analyzed with a larger sample.  
The sample‟s composition was limited by several restrictions. It was restricted 
ethnically, as it represented only two ethnic groups (Caucasian, Latino). There was also a 
significantly uneven distribution of males and females which was not consistent with 
ALL or general population estimates.  Since the sample is not matched to ALL survivor 
population or general population, it is much more difficult to make generalizations. 
The data from this study also represent a single point in time, making baseline and 
longitudinal comparisons impossible. That is to say, while statistically significant deficits 
in working memory were not present at the time of testing for this study, there may have 
been a change in skills present before treatment that could not be detected using a single 
data point.  
 Additionally, as discussed earlier, the measure used for visual working memory 




memory. The design of the subtest allows the examinee the advantages of (1) seeing the 
stimuli multiple times and (2) allowing for some response error. A recommended 
beneficial, albeit difficult, task for test development may be the creation of a task that 
more purely measures visual working memory.  
 These limitations raise questions about accuracy and generalizability of the results 
of this study. The nonsignificant results may reflect a true absence of working memory 
problems in this sample, but the restriction of available data may also have hindered the 
analyses‟ ability to detect accurate results. 
Implications 
 While this study purported several hypotheses, none of them resulted in 
significant outcomes. It is important to acknowledge that one explanation for these 
nonsignificant results across hypotheses may well be that survivors of ALL do not suffer 
from late effects in the area of working memory. However, this does not imply that 
research in this area should cease. Conversely, implications for future research and 
clinical care are discussed in light of the limits of this particular study. 
As is true for most studies, a large sample size is ideal, and future studies should 
obtain the largest N possible. A major benefit of a large sample size is the increased 
power to find significance. Although ALL is the most commonly diagnosed malignancy 
in childhood, it is still fairly rare amongst the general population, and therefore, a large 
sample size may be well acquired through a multisite study. This larger N should better 




socioeconomic status, geographic location, and other population characteristics to allow 
for generalization of results. 
 The addition of a control group is another way to strengthen future research. For 
this study, a control group would have allowed for between-group comparisons to be 
conducted. These comparisons between IQ and working memory in both survivors and 
typical children could better allow determination of whether any significant findings are 
unique to the ALL population. Additionally, differences between overall cognitive 
functioning between groups could be tested to determine if any differences were present.  
Future studies should aim to include a control group whenever possible. 
 In this study, since the participant‟s IQ and working memory were measured 
once, it is unclear whether any deficits or strengths were present before treatment for 
ALL began. Unfortunately, much of the ALL research has been conducted in a similar 
fashion. Since late effects, by their nature, occur after completion of treatment, an 
estimate of premorbid functioning (baseline testing) would provide valuable information. 
Additionally, multiple points of data throughout survivorship, or serial evaluations, 
would be beneficial as they would allow for any patterns of loss of functioning over time 
to be studied. It would be worthwhile for future studies to have baseline testing and at 
least one data point during survivorship, if not more. Fortunately, given the increased 
knowledge of cognitive late effects, many hospitals and clinics are now recommending 
that a baseline neuropsychological evaluation be conducted prior to the completion of 
treatment for ALL. Additionally, follow-up evaluations throughout survivorship are 




 Future research might create models of hypothesis testing that allow for 
comparisons between different treatments types and intensities to determine whether 
specific treatments affect working memory in different ways. This study did not account 
for differences in intensity of treatment due to the study design and small available 
sample. Although this study‟s sample was comprised of similar participants, in that they 
all received only chemotherapy during treatment and had no recurrence of cancer, there 
were differences in the types and intensity of treatment received, which were not 
accounted for. 
The unexpected finding that verbal memory was better developed than nonverbal 
memory implies that a more “pure” measure of visual working memory that allows for 
visual stimuli to only be present once may need to be created and utilized to truly 
measure nonverbal working memory. An additional implication is that the relationship 
between verbal and nonverbal working memory should continue to be studied in future 
research to better understand the nature of these differences. 
Although the results of this study are limited, implications can be gleaned from 
this research, most of which pertain to research conducted in the future. While results of 
main analyses were nonsignificant, the fact that Digit Span Backward (DSB) was 
significant across hypotheses does suggest that working memory may indeed be 
negatively impacted in survivors of pediatric ALL. Importantly, amongst the measures of 
working memory assessed, DSB appears to have been the most sensitive, stringent and 




The results of this study may impact the various professionals that work with 
survivors of ALL if working memory is damaged. First, clinicians should know that 
working memory may be negatively impacted in this population. They should understand 
that working memory is essential for academic achievement (mathematics in particular), 
other academic activities such as note-taking, and daily-living skills, such as properly 
sequencing and carrying out daily routines. Clinicians should also appreciate the need for 
baseline and follow-up evaluations and heed the importance of making recommendations 
specific to working memory deficits if they are present for an individual.  
Second, individuals who interact with survivors of ALL on a daily basis, such as 
parents and teachers, should be provided with psychoeducation on how to identify if 
working memory is impaired, how working memory and other cognitive deficits may 
manifest, what life areas may be affected, and how they can support the needs of these 
individuals in regards to working memory deficits, in combination with other potential 
cognitive deficits. This way, for individuals who may have deficits in working memory, 
even if they are slight, can be identified and supported.  
Finally, the results of this study have implications for research, not only in social 
science, but medical science as well. As outlined earlier, social science researchers 
should continue to study working memory in survivors of ALL with greater, more 
representative samples and more complex statistical methods. Medical researchers should 
continue to try to refine the balance between treatment that increases survivorship while 
reducing the quantity of neurotoxic agents (and possible late effects) given to individuals 





 The primary goal of this study was to investigate working memory ability in 
survivors of pediatric Acute Lymphoblastic Leukemia (ALL) who were treated with 
chemotherapy only. Survivors‟ working memory, as compared to overall cognitive 
functioning, was explored in addition to comparisons between verbal and nonverbal 
working memory and gender comparisons. While the main analyses were nonsignificant, 
the findings of this study nevertheless have implications for continued research and 
potentially disease treatment, assessment, and intervention of survivors of pediatric ALL 
in the future. 
Many results of this study were nonsignificant, which may be due to a lack of 
working memory deficits in survivors of ALL, or it may be attributed to methodological 
issues. Regardless of the cause of these nonsignificant outcomes, future research is 
implicated to determine whether or not deficits truly exist. If future research mirrors the 
nonsignificant findings of this study, the results would be a cause for celebration amongst 
survivors of ALL. An important executive cognitive skill would be intact and a research 
base for resiliency in survivors of ALL treated with chemotherapy alone could begin.  
Conversely, if future studies that implement stronger methodology find that there are 
impairments in working memory, then it will have implications for future identification 
and treatment of affected individuals. Therefore, working memory in survivors of ALL 
treated with chemotherapy only should continue to be examined in future research with 





The interesting finding that Digit Span Backward (DSB) from the WISC-IV was 
impaired when compared to other scales in this study may imply that impairments do 
exist on a more sensitive measure of working memory.  Since deficits in working 
memory are linked to academic achievement, classroom performance, and daily 
functioning, this finding needs to be considered as individuals in this population may 
require specific modifications and interventions should a deficit in working memory be 
present. Implications of this finding may affect clinicians, parents, teachers, and social 
and medical science researchers.  
Overall, this study produced one of the first looks at working memory in survivors 
of pediatric ALL treated solely with chemotherapy and results highlighted potential 
deficits or absence of deficits in working memory in this population. The findings of this 
study support the need for continued research in working memory in survivors of ALL to 






           Consent Form 
Parent/Guardian Informed Consent Agreement 
Please read this consent agreement carefully before you decide to allow your 
child to participate in this research study.  Your child will also receive an assent 
form; please review the assent form with your child. 
 
Hello, 
On behalf of the University Of Texas at Austin and the LIVESTRONG Survivorship 
Center at Dell Children’s Blood & Cancer Program of Central Texas we are inviting you 
to participate in a potentially important research study. Our names are Daniel Garrison 
and Amanda Winter and we are doctoral students in School Psychology (Educational 
Psychology Department) at the University of Texas at Austin.  The purpose of this study 
is to investigate the potential long-term effects of cancer treatments in survivors of 
childhood ALL. This study is part of our doctoral dissertations and will potentially lead to 
a better understanding of the effects of treatment toxicity on the brain. Specifically, we 
will be looking at the following abilities: working memory (the ability to manipulate 
information in memory), processing speed (the ability to efficiently process information), 
and executive function (the ability to plan, organize, monitor, and self-regulate one's 
actions to achieve a goal).  
In order to gather this information from these specific abilities, your child we be asked to 
complete a full neuropsychological assessment that consists of various tests that provide 
information on how to solve problems with and without using your words. Many children 
find these tests to be interesting and even fun and will provide information on how 
he/she thinks and learns. Testing will require approximately 150 minutes of your child's 
time and effort. This testing will take place in a quiet room at Dell Children's Blood and 
Cancer Program of Central Texas. Your child may take a break at any point during the 
evaluation. 
As your child completes the assessment, you will be asked to fill out a brief history form 
and questionnaire requiring approximately 30 minutes of your time. In addition, you will 
given a separate, brief questionnaire and a self-addressed, stamped envelope, to give to 
your child's teacher to complete and return. 
Upon completion of the assessment, we will score and interpret the results and provide 
you with a comprehensive, integrated report, which you may use as you wish.  Some 
parents use such a report to assist in the development of any needed educational 




regarding the results and any of their implications. The neuropsychological assessment, 
report, and feedback will be provided at no charge. Each assessment will be supervised 
by Rachel Robillard, Ph.D., L.S.S.P.(Credentialed Psychologist, Seton Healthcare 
Systems). 
Please read the following carefully and thank you in advance for your consideration in 




Daniel A. Garrison, M.A.    Amanda L. Winter, M.A. 
Doctoral Candidate     Doctoral Candidate 
The University of Texas at Austin                              The University of Texas at Austin 
School Psychology     School Psychology 
Educational Psychology    Educational Psychology 







Purpose of the research study: The purpose of this study is to examine working 
memory, speed of information processing, and executive function in survivors of 
childhood ALL. These abilities have implications for a child's educational, social, 
emotional, and daily functioning. This investigation also aims to investigate risk factors 
that may make it more likely to develop such problems in the future. Examples of 
potential risk factors include intensity of treatment, age at diagnosis, and gender.  
What will you and your child do in the study: If you and your child consent to 
participate in this investigation, you will be asked to attend a single assessment session 
at Children's Blood & Cancer Program Dell Children's Medical Center of Central Texas in Austin, 
TX. At that time, your child will complete a neuropsychological evaluation that will take 
approximately 150 minutes. You, as the parent/guardian, will be asked to complete two 
additional surveys that will take approximately 30 minutes total. If you also consent to 
and sign an “Exchange of Information” form, one of your child’s teachers will be sent a 
similar survey that will ask him or her to answer questions regarding your child’s 
neurocognitive functioning in the school system. This survey will take approximately 30 
minutes for your child’s teacher to complete and you will be provided with a self-
addressed stamped envelope to be used in returning the teacher survey through U.S. 
Mail.  
The performance on neuropsychological tasks, answers to all surveys, as well as any 
demographic information that is collected, will be used to determine any problematic 
long-term effects that pediatric cancer survivors may or may not experience that may be 
associated to their completed treatment. This study will also require our access to your 
child's cancer treatment summary in their medical history. We will only be looking at the 
date of diagnosis, date of last treatment, and the dosage of treatment received. 
The primary investigators may also contact you to answer any questions or address any 
concerns you have.  You are also encouraged to contact the investigator if you have any 
questions and/or concerns about you or your child’s participation.  
While it is important to receive all materials fully completed, you and your child may skip 
any question or stop any evaluation task that may make you or your child feel 
uncomfortable. You and your child may stop the any part of the evaluation at any time.  
Confidentiality: All information attained in this study will be handled confidentially.  Your 
information will be assigned a code number and the list connecting your child’s name 
and/ or your name to this code will be kept in a locked file. When the study is completed, 
this list will be destroyed. Your child’s name and/or your name will not be used in any 





Researchers are required by Texas state law and professional ethics codes to report to 
Child Protective Services (or other appropriate regulatory agency) all instances of 
alleged child abuse and neglect. Please not that if your child is believed to be at risk for 
emotional, psychological or possible physical harm or neglect, then the investigator will 
report this information to the attending physician, Child Protective Services, and any 
other necessary regulatory agencies. Please note when a child reports neglect or being 
harmed, participants cannot stop the referral of their child's case to the authorities and 
any subsequent actions taken.  
If you have any questions about the study, concerns, or to withdraw from the study, you 
can call Rachel Robillard, Ph.D. at (512)-934-7858 or you may contact one of us.  
If you have questions about your rights as a participant, please contact Lisa Leiden, 
Ph.D., Chair, The University of Texas at Austin Institutional Review Board for the 
Protection of Human Subjects, (512)-471-8871.  
If you consent to it below, the data resulting from your participation may be made available 
to other researchers in the future.  
Time required: The forms included in a full neuropsychological assessment will require 
approximately 30 minutes of your time. Forms to be completed by your child's teacher 
will require approximately 30 minutes of their time. Your child should expect to spend 
approximately 150 minutes to complete the neuropsychological assessment.  
Benefits:  The study may provide beneficial information on the neuropsychological 
functioning of your child. You will receive a full neuropsychological evaluation and report, 
at no charge, that may be used to inform the development of any educational planning or 
interventions, if needed. The study may add to research on any long-term cognitive 
effects that pediatric ALL survivors may experience.  In addition, results of this 
investigation may add to the development of future treatment protocols that reduce the 
likelihood of such problems as a result of treatment.  
Risks: Anticipated risks in this study may include minimal psychological discomfort 
related to questions about current neurocognitive problems. Your child may also 
experience mild fatigue or frustration in response to the duration of the evaluation. 
Because some questions may be of a sensitive nature, you and your child are not 
required to answer those items. In the event that these questions produce psychological 
discomfort, you may have your concerns addressed and/or receive debriefing 
consultation by Dr. Rachel Robillard, Ph.D. (512- 934-7858) or Dr. Cindy Carlson, Ph.D., 
(512-471-0276) licensed psychologists and university faculty sponsors. 
Voluntary participation: You and your child’s participation in this study (as well as the 




Right to withdraw from the study: You are free to refuse to be in this study. You are 
free to discontinue participation for any reason at any time, and your refusal or 
discontinuation will not influence current or future relationships with The University of 
Texas at Austin or Dell Children's Hospital.  
Please check the appropriate box indicating that YES you have read this letter and are 
giving permission for you and your child to participate in this study or NO you do not 
want to participate. Regardless of your decision, please sign this form indicating your 
choice. 
How to withdraw from the study: If you and/or your child want to withdraw from the 
study, tell the researcher.  There is no penalty for withdrawing. If you would like to 
withdraw after your materials have been submitted, please contact the principal 
investigators, Daniel A. Garrison or Amanda L. Winter at austinoncology@gmail.com  



















STATEMENT OF SUBJECT CONSENT 
Do not sign this consent form after: (            ) 
 
1. This study has been explained to me. I voluntarily agree to take part in this study. 
I have had the opportunity to ask questions. I understand that the investigators 
listed on this form can answer future questions I may have about this study and 
my child‟s rights. By signing this form I understand that I am not giving up any of 
the patient rights listed on the attached “Patient Bill of Rights”.  I understand that 
signing this consent does not take the place of any other consent forms I have 
signed. I understand that I will be given a copy of this consent to keep and that if I 
request it, I will be given a copy of the study protocol.  
 
  YES I give permission for my child, __________________, and me to 
participate in this study. This includes permission for (1) my child to 
participate in the assessment, (2) permission for the researchers to access 
my child's cancer treatment history in his/her medical records, (3) 
permission for my child's teacher to complete a questionnaire regarding 





 NO I do not give permission for my child, _______________, and me to 




__________________________        ____________________________ 
        Signature of Parent/Guardian  Printed Name 
 
 __________________________ ____________________________ 




If you have questions about the study, contact the Principal Investigators: 
Daniel A. Garrison    Amanda L. Winter 
School Psychology Program   School Psychology Program 
1 University Station D5800   1 University Station D5800 
Austin, TX 78712    Austin, TX  78712 
Telephone: (512) 773-1267   Telephone: (512)-917-0766 
 
Faculty Advisors: 
Rachel Robillard, Ph.D., LSSP  Cindy Carlson, Ph.D, Professor 
4810 B Spicewood Springs Rd.  Department of Educational Psychology,  
Austin, TX 78759    College of Education 
robillard@alumni.utexas.net   1 University Station D5800 
Telephone: (512) 934-7858   Austin, TX 78712 
       cindy.carlson@mail.utexas.edu 
      512-471-0276 
 
 
If you have questions about your rights in the study, contact: 
Sharon Horner, RN, PhD   Jody Jensen, Ph.D., Chair 
Brackenridge Hospital‟s IRB Chair  The University of Texas at Austin 
601 E 15th Street     IRB for the Protection of Human Subjects 
Austin, Texas 78701    (512) 232-2685 
(512) 324-7991 
 
The University of Texas at Austin 
Office of Research Support 





EXPERIMENTAL SUBJECTS BILL OF RIGHTS 
                      What are your child’s rights as a research subject? 
The following is the Experimental Subject's Bill of Rights.  Please read and keep this 
information for future reference.  Although the principal investigators may be available to 
answer related questions, those pertaining to subject rights listed below should be 
addressed to the Chair of the Brackenridge Institutional Review Board, Sharon Horner, 
RN, PhD at (512) 324-7991. 
1. To be told what the study is trying to find out. 
 
2. To be told what will happen to your child and whether any of the procedures, drugs, 
or devices that are different from what would be used in regular practice. 
 
3. To be told about the frequent and/or important risks, side effects or discomforts of the 
things that will happen to your child for research purposes. 
 
4. To be told if your child can expect any benefit from participating and, if so, what the 
benefit might be. 
 
5. To be told the other choices your child has and how they may be better or worse than 
being in the study. 
 
6. To be allowed to ask questions about the study, both before agreeing to volunteer and 
during the study. 
 
7. To be told what kind of medical treatment is available if your child has any problems. 
 
8. To refuse to have your child participate at all or to change your mind about his/her 
participating after the study is started.  This decision will not affect your child‟s right 
to receive the care he/she would receive if he/she were not in the study. 
 
9. To receive a copy of the consent form. 
 









I have fully explained this clinical research study to the participants, and in my judgment, 
and theirs, there is sufficient information regarding the risks and benefits to make an 
informed decision.  I will inform the participants in a timely manner, of any changes in 
the risks and benefits of this clinical research study. 
 
___________________________     ________________ _______     _______ 






Minor Informed Assent Agreement 13-17 
Please read this assent agreement with your parent(s) or guardian(s) before you 
decide to participate in the study.  
 
WHAT IS THIS INVESTIGATION ABOUT? Hello, our names are Daniel Garrison and 
Amanda Winter and we are graduate students in School Psychology at the University of 
Texas at Austin. We would like to tell you a little about our study.  You may remember 
that when you were being treated for cancer, you may have sometimes experienced 
negative side effects of treatment such as hair loss, vomiting, loss of appetite, 
stomachaches, pains, etc.   
You may also have experienced problems with your thinking, memory, concentration, 
balance, speech and vision problems. Fortunately, a lot of those effects went away when 
you finished treatment; for some, however, those side effects remain.  Although we know 
a lot about the potential effects on the body caused by treatment, we still do not know a 
lot about how your experience and the treatments you received (like chemotherapy 
and/or radiation) affect thinking and memory in children and adolescents years later.   
WHAT DO I HAVE TO DO? As part of our study, you will be asked to complete a 
neuropsychological assessment that will take approximately 150 minutes of your time. 
During the assessment, you will be asked to complete several problem-solving tasks 
using language, your memory, your ability to do things quickly, as well as your ability to 
figure out patterns and puzzles. Most people who complete an assessment find it to be 
an enjoyable experience. You can do it all at once, or you can take breaks and complete 
the assessment in chunks. We will also ask one of your parents, and one of your 
teachers to fill out some questionnaires about your thinking and feelings at home and at 
school. 
RISKS AND BENEFITS: If you participate in the study, you may get tired and some of 
the tasks may seem sort of hard. You may take a break, or stop, at any time. You may 
also be uncomfortable if you are not used to answering questions about your emotions.  
However, if you get to a question and you do not want to answer it, you can skip it.  If 
you start the assessment and realize you don’t want to complete it, you can stop at any 
time with no penalty to you or your family.   If you continue to experience discomfort, 
your parent/guardian can contact Dr. Rachel Robillard, Ph.D. (512- 934-7858) or Dr. 
Cindy Carlson, Ph.D., (512-471-0276) licensed psychologists and university faculty 





If you participate in this study, there will not be any direct benefit to you.   You and your 
parents, however, will get a full report of how you did and what that means. If some 
things are harder for you now that you’re done with treatment, it can help get you help 
you need. Your participation in this testing will help us better understand thinking, 
learning and memory in cancer survivors, which may help us prevent those problems 
from happening in children and adolescents who may be diagnosed with cancer in the 
future.    
CONDIFENTIALITY: The information that you give to us during this study will be kept 
private.  Your name will not be used.   
DO I HAVE TO PARTICIPATE? You don’t have to participate in this study and you can 
stop doing the study at any time.  If you want to stop doing the study, tell your parents 
and one of us, Daniel Garrison or Amanda Winter.  If you choose to stop before we are 
finished with the study, any testing you already did will be destroyed.  There is no 
penalty for stopping.  If you decide that you don’t want your materials in the study but 
you already turned them in, contact Daniel Garrison or Amanda Winter at 
austinoncology@gmail.com. 
Agreement: (Parents/Guardians: Please read aloud to your child if they are unable 
to read) 
 I understand that my Mom, Dad or Guardian has said that it is okay for me take 
part in this study about the effects of my cancer treatment. 
 I understand what this study is about. 
 I understand that I am agreeing to complete an assessment that will last 150 
minutes. 
 I am going to be in this study because I want to. 
 I have been told that I can stop being a part of this study anytime I want to.  
Nothing will happen to me if I want to stop.  
 
__________________________  ____________________________ 
Signature of Child    Printed Name of Child 
 
__________________________  ____________________________ 
Signature of Parent/Guardian   Printed Name of Parent/Guardian 
 
 _______________ 




Minor Informed Assent Agreement 6-12 
Please read this paper with your Mom or Dad.   
 
Hello, our names are Daniel Garrison and Amanda Winter and we are students at the 
University of Texas. We are working on a study to learn about kids like you who were 
treated for cancer. You probably remember that the medicine you took to fight the 
cancer had side effects that made you feel sick.  Most of the these side effects go away 
when you stop treatment, but for some children, they may have other side effects on 
their thinking and memory, even though they have stopped treatment.  For some kids, 
this can make learning harder once they return to school, even if the doctor has told 
them that their cancer is gone and that things are back to normal.  
We don’t really know if or why this might happen, but we would like to find out. If we find 
that kids like you are having a hard time with different ways of thinking and remembering 
things long after you finished treatment, then we and others can use that information to 
develop ways keep these things from happening at home and school. 
As part of our study, we would like to ask you to complete a bunch of different activities, 
like puzzles and games.  Most people who complete these activities usually say they 
have fun answering the different questions and trying the different activities and puzzles. 
It should take you about 2 and a half hours to complete, but you can always take breaks 
and come back to it later if you get tired. 
RISKS/BENEFITS: It may seem like some of the activities we do are hard and like it is 
taking a long time. Also, some questions about problems might make you feel 
uncomfortable or sad. If you start to feel tired, sad or nervous during any activity, you 
can stop at any time and tell your parent or guardian. Answering these questions won’t 
help you directly, but you and your family will learn a lot about how think and learn. Also, 
hopefully your answers will help us learn more about children and any problems with 
thinking or learning they might have after finishing treatment.  
CONFIDENTIALITY: Your answers to our questions during this study will be kept 
private.  Your name will not be used, and no one who reads about our study will know it 
was you.  
Your answers to our questions during this study will not have your name on it, so we 
won’t know what answers you give.  
DO I HAVE TO PARTICIPATE IN THIS STUDY? You don’t have to participate in this 
study.  You can stop doing the study at any time. If you want to stop doing the study, you 




with this study, any answers you already gave will be destroyed.  You will not get in 
trouble for stopping.  If you decide that you don’t want your materials in the study but you 
already turned them in, tell your parents to contact us.  
Agreement: (Parents/Guardians: Please read aloud to your child if they are unable 
to read.) 
 I understand that my Mom, Dad or Guardian has said that it is okay for me take 
part in this study about the effects of my cancer treatment.   
 I understand what this study is about. 
 I understand that I will be testing for 2 and a half hours. 
 I am going to be in this study because I want to. 
 I have been told that I can stop being a part of this study anytime I want to.  




__________________________  __________________________ 
Signature of Child    Printed Name of Child 
 
 
__________________________  __________________________ 


















Descriptive Statistics of the Sample 
Table 2 
Descriptive Statistics of Sample 
 
Variable Mean (n = 19) SD Range 
 
Age at Diagnosis (years) 5.19 2.60 1.50 – 10.83 
 
Age at End of Treatment (years) 8.04 2.41 4.75 – 12.67 
 
Age at Testing (years) 14.75 3.24 10.00 – 21.83 
 







Ethnic Makeup of the Sample 
 
Table 3 
Ethnic Makeup of Sample 
 
Ethnicity N Percentage of Sample 
 
Caucasian 15 79 
 







Descriptive Statistics of Working Memory Composite Scores 
  
Table 4  
Descriptive Statistics of Working Memory Composite Scores 
 
 
Variable Mean (n = 19) SD 
 
WMCa -0.479 0.7627 
 
VWMCb -0.1158 0.9023 
 
NVWMCc 0.1584 0.7646 
 
aWorking Memory Composite 
bVerbal Working Memory Composite 







Descriptive Statistics by Gender 
 
Table 5 
Descriptive Statistics by Gender 
 
 





















-0.56 – 0.44 
Verbal WMC 
 
-.0139 (1.01109) -1.17 – 1.65 -0.4010 (0.45092) -0.84 – 0.17 
NVWMC 
 







Intercorrelations Among All Variables 
 
Table 6 
Intercorrelations Among All Variables 
 
Variable 
(1) (2) (3) (4) (5) (6) 
 
(1) FSIQ 
1.00      
 
(2) WMC 
0.646** 1.00     
 
(3) VWMC 
0.621* 0.991** 1.00    
 
(4) NVWMC/Visual Sequential Memory 
0.492* 0.575** 0.462* 1.00   
 
(5) Digit Span Backward 
0.252 0.540* 0.532* 0.329 1.00  
 
(6) Letters Backward 
0.628** 0.976** 0.987** 0.441 0.391 1.00 
** Correlation is significant at the 0.01 level (2-tailed). 
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